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Resumo 
 
 A modulação da libertação do ácido γ-aminobutírico (GABA) de 
interneurónios inibitórios, mediada pelo receptor de canabinoides do 
tipo 1 (CB1), é importante para a integridade da memória espacial 
dependente do hipocampo. Apesar dos receptores de adenosina do 
tipo 1 (A1) desempenharem um papel central na regulação da 
transmissão sináptica excitatória no hipocampo, os receptores A1 
localizados nos neurónios GABAérgicos não influenciam 
directamente a libertação de GABA. Os receptores CB1 e A1 são os 
principais receptores envolvidos nos efeitos de duas das substâncias 
psicoactivas mais consumidas em todo o mundo: Δ9-
tetrahydrocannabinol (THC, um agonista do receptor CB1) e cafeína 
(um antagonista dos recetores de adenosina). Eu primeiro testei a 
hipótese de que uma interacção entre A1 e CB1 influencia a 
libertação de GABA e de glutamato no hipocampo de rato. Observei 
que a activação do receptor A1 atenuou a inibição da libertação de 
GABA e de glutamato dependentes do receptor CB1, e que esta 
interacção se manifesta ao nível da activação de proteínas G. 
Utilizando abordagens in vivo, ex vivo e in vitro, seguidamente 
investiguei as implicações funcionais da interacção entre A1 e CB1 
que podem surgir após o consumo crónico de cafeína. A 
administração crónica de cafeína em ratinhos (i.p., 3 mg/kg/dia, 
durante 15 days, >12h antes dos ensaios) levou a um aumento dos 
	  x	  
défices cognitivos induzidos por administração aguda de THC num 
teste de memória espacial de curta duração. Este aumento do efeito 
do THC foi prevenido pela pré-administração aguda de um 
antagonista do receptor A1. Apesar deste efeito in vivo, a 
administração crónica de cafeína induziu também uma redução no 
número dos receptores CB1 em tecido do cortex e hipocampo, assim 
como uma atenuação da ligação de proteínas G ao receptor CB1. O 
número de receptores A1 aumentou com a administração crónica de 
cafeína. Este estudo demonstra que os receptores A1 exercem um 
efeito modulatório negativo sobre a inibição da libertação de GABA e 
glutamato dependente da activação de receptores CB1. Este estudo 
também apresenta a primeira evidência de alterações no sistema 
canabinoide, em cortex e hipocampo, induzidas pelo consumo 
crónico de cafeína, com implicações funcionais para a função da 
memória espacial. 
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Abstract 
 	   The cannabinoid CB1 receptor-mediated modulation of γ-
aminobutyric acid (GABA) release from inhibitory interneurons is 
important for the integrity of hippocampal-dependent spatial memory. 
Although adenosine A1 receptors have a central role in fine-tuning 
excitatory transmission in the hippocampus, A1 receptors localized in 
GABAergic cells do not directly influence GABA release. CB1 and A1 
receptors are the main targets for the effects of two of the most 
heavily consumed psychoactive substances worldwide: Δ9-
tetrahydrocannabinol (THC, a CB1 receptor agonist) and caffeine (an 
adenosine receptor antagonist). I first tested the hypothesis that an 
A1-CB1 interaction influences GABA and glutamate release in the 
hippocampus. I found that A1 receptor activation attenuated the CB1-
mediated inhibition of GABA and glutamate release and this 
interaction was manifested at the level of G-protein activation. Using 
in vivo, ex vivo, and in vitro approaches, I then investigated the 
functional implications of the adenosine-cannabinoid interplay that 
may arise following chronic caffeine consumption. Chronic 
administration of caffeine in mice (i.p., 3 mg/kg/day, for 15 days, 
>12h before trials) led to an A1-mediated enhancement of the CB1-
dependent acute disruptive effects of THC on a short-term spatial 
memory task, despite inducing a reduction in cortical and 
hippocampal CB1 receptor number and an attenuation of CB1 
	  xii	  
coupling with G-protein. A1 receptor levels were increased following 
chronic caffeine administration. This study demonstrates that A1 
receptors exert a negative modulatory effect on CB1-mediated 
inhibition of GABA and glutamate release, and provides the first 
evidence of chronic caffeine-induced alterations on the cannabinoid 
system in cortex and hippocampus, with functional implications in 
spatial memory. 
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1. Introduction 
 
1.1. The endocannabinoid system 	  
 The endocannabinoids represent a group of lipid messenger 
molecules (Figure 1.1.2) that derive from the cellular membrane and 
act retrogradely, on-demand, to activate presynaptic cell surface 
receptors (for a review, see Piomelli, 2003). The endocannabinoid 
system is widespread throughout the vertebrate species (Elphick and 
Egertová, 2001, 2005), with a broad spectrum of physiologically 
relevant roles in various body tissues, but particularly in the central 
and peripheral nervous system (Freund et al., 2003; Piomelli, 2003). 
Cannabinoid receptors are also targeted by Δ9-tetrahydrocannabinol 
(THC, Figure 1.1.1), the main active constituent from the plant 
Cannabis sativa (cannabis, marijuana, hemp).  
	  
 
Figure 1.1.1. Chemical structure of Δ9-tetrahydrocannabinol (THC). 
The pure THC isomer is also known as dronabinol, and is one of only two 
cannabinoids licensed for medical use, the other being its synthetic  
analogue, nabilone (Pertwee, 2005).
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 THC is one of the most widely consumed substances worldwide 
(Leggett, 2006), and is used for recreational or medicinal (Di Marzo 
and Petrocellis, 2006) purposes. The endocannabinoid system has 
been therapeutically exploited for thousands of years, through the 
consumption of cannabis (Nagy et al., 2008). Its biochemical and 
physiological characterization began with the structural 
characterization of THC (Gaoni and Mechoulam, 1964). Due to its 
hydrophobic nature, the mechanisms of action of THC were, for 
years, thought to involve interference with the cell membranes, but 
not the activation of a specific receptor (see Piomelli, 2003). A 
cannabinoid-binding site in the brain was then pharmacologically 
identified (Devane et al., 1988) and, soon after, two specific 
cannabinoid GPCRs were cloned and characterized: CB1 (Matsuda 
et al., 1990), and CB2 (Munro et al., 1993).  
 The main endogenous cannabinoid ligands (endocannabinoids 
Figure 1.1.2) are N-arachidonoylethanolamide, (anandamide, 
Devane et al., 1992) and 2-arachidonoylglycerol (2-AG, Mechoulam 
et al., 1995; Sugiura et al., 1995). Other, lipid-derived molecules 
(Hanus and Mechoulam, 2010) and peptides (Heimann et al., 2007; 
Gomes et al., 2009) have been identified as cannabinoid ligands, 
although with less prevalence. Anandamide acts as a partial 
cannabinoid receptor agonist, while 2-AG is a full cannabinoid 
receptor agonist and is thought to be the most relevant of the 
endocannabinoids (Sugiura, 2008). 
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 Anandamide (Figure 1.1.2a) is mostly synthesized from N-
arachidonoyl phosphatidylethanolamine (NAPE) by phospholipase D 
(Okamoto et al., 2004), but also from arachidonic acid and 
ethanolamine by fatty acid amide hydrolase (FAAH), acting in 
reverse direction (Cravatt et al., 1996; Kurahashi et al., 1997). 2-AG 
(Figure 1.1.2b) is mainly synthesized from arachidonic acid-
containing membrane phospholipids, such as inositol phospholipids 
by the combined actions of phospholipase C and diacylglycerol 
lipase, or phospholipase C and phospholipase A1 (reviewed by 
Sugiura, 2008).  
  Endocannabinoids are generated postsynaptically, in a Ca2+-
dependent manner, in response to a depolarizing stimulus (for a 
review, see Freund et al., 2003; Sugiura, 2008), and diffuse across to 
the presynaptic terminals, where they act as retrograde messengers 
(Kano et al., 2009). However, endocannabinoids may also act as 
autocrine signals for the regulation of the own activity of some 
neurons, by self-inhibition (Bacci et al., 2004; Marinelli et al., 2009).  
 The actions of endocannabinoids are terminated by a yet 
unidentified process of facilitated transport inside the cell, where they 
are metabolized by hydrolytic enzymes (for a review, see Fowler and 
Thors, 2008). Anandamide is mainly hydrolyzed by FAAH, while 2-
AG is mostly hydrolyzed by monoacylglycerol lipase in the brain, 
although it can also be hydrolyzed by FAAH (Fowler and Thors, 
2008).  
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Figure 1.1.2. Synthetic pathways of (a) anandamide and (b) 2- 
arachidonoylglycerol (2-AG). (a) Anandamide is mostly synthesized from 
N-arachidonoyl phosphatidylethanolamine (NAPE) by phospholipase D. (b) 
2-AG is mainly synthesized from phosphatidylinositol by the combined 
actions of phospholipase C (PLC) and diacylglycerol lipase (DGL), or 
phospholipase C and phospholipase A1 (PLA1) (figure adapted from Freund 
et al., 2003; reviewed by Sugiura, 2008). 
a	   b 
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1.1.1. Cannabinoid receptors 
 
 Two specific cannabinoid receptors have been cloned and 
characterized to date: CB1 (Matsuda et al., 1990), and CB2 (Munro et 
al., 1993), and both are of the G-protein coupled receptor (GPCR) 
superfamily, containing seven-transmembrane-domains (Howlett et 
al., 2002). Recent evidence also indicates that the orphan receptor 
GPR55 is a cannabinoid ligand-sensitive receptor, although its 
classification as a cannabinoid receptor remains controversial (Ross, 
2009). 
 The CB1 and CB2 receptors regulate the activity of intracellular 
effectors through the activation of inhibitory Gi/oα proteins, but CB1 
receptors can also couple to stimulatory Gs proteins, as a function of 
ligand availability or heteromeric receptor interactions (for a review, 
see Howlett, 2005; Irving et al., 2008). Both receptors trigger identical 
intracellular effector cascades, by the inhibition of adenylyl cyclase 
activity (Howlett, 2005). However, CB1 receptors can also inhibit 
voltage gated Ca2+ channels (VGCCs, Mackie and Hille, 1992) and 
activate inwardly rectifying K+ channels (Mackie et al., 1995). 
 The density and widespread expression of CB1 receptors in the 
central nervous system (CNS) is remarkably high (Figure 1.1.3), and 
it has been described as the most predominant GPCR in the 
mammalian brain (Herkenham et al., 1990; Herkenham et al., 1991). 
CB1 receptors are thus considered the most important for the 
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regulation of endocannabinoid functions in the CNS, and also for the 
effects of exogenous cannabinoids, such as THC (reviewed by 
Marsicano and Kuner, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.3. Autoradiographs showing cannabinoid CB1 receptor 
distribution in the rat brain. (a) CB1 receptor marked by the tritiated 
ligand CP-55,940 in an in vitro binding assay described by Herkenham et 
al. (1990). (b) rat brain slice, of a similar plane of observation, hybridized 
with a CB1-specific oligonucleotide probe. Legend: globus pallidus (GP), 
entopeduncular nucleus (Ep), substantia nigra pars reticulata (SNR), 
hippocampus (Hipp), caudate putamen (CPu). Note that highest levels are 
found in the basal ganglia structures (GP, Ep, SNR, CPu), cerebellum, 
b a 
b 
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cortex and hippocampus. Lack of CB1 mRNA-expressing cells in the GP, 
Ep, and SNR indicate that the receptors in these areas are located on axon 
terminals (arrow), while the mRNA expressing cells reside in the CPu 
(adapted from Freund et al., 2003). 
 
 The CB1 receptor is predominantly located in presynaptic nerve 
terminals (Freund et al., 2003), and its expression is particularly high 
in corticolimbic areas, basal ganglia, cerebellum and brain stem 
(Marsicano and Kuner, 2008). The distribution pattern of CB1 
receptors in the brain is closely correlated to the physiological and 
behavioural effects of endogenous and exogenous cannabinoid 
ligands. Some of the functions where the CB1 receptor has been 
implicated include neural development (Harkany et al., 2008), 
neuroprotection (Katona and Freund, 2008), synaptic plasticity 
(Heifets and Castillo, 2009), learning and memory (Moreira and Lutz, 
2008), appetite regulation and energy metabolism (Matias et al., 
2008). For a recent comprehensive review of cannabinoid 
physiology, see Kano et al. (2009)  
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 Figure 1.1.4. Autoradiograph showing CB2 receptor mRNA 
expression in the mouse brain. Note that there is no detectable 
expression of CB2 receptors in the brain. (adapted from Howlett et al., 
2002). 
 
 There is some evidence that CB2 receptors are also, to a much 
lesser degree, expressed in the brain (Gong et al., 2006; Onaivi et 
al., 2006). However, there are no detectable amounts of CB2 
receptor mRNA in the brain (see Howlett et al., 2002, Figure 1.1.4). 
The CB2 receptors are generally considered to be regulators of 
immune responses, given their predominant distribution in immune 
cells. Furthermore, application of CB2 receptor agonists does not 
have any effect in various neuropharmacological studies on the CNS 
(for a review, see Marsicano and Kuner, 2008; Prather, 2008). 
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1.1.2. Functions of CB1 receptor signalling in the hippocampus 	  
 Hippocampal CB1 receptors are primarily found in presynaptic 
terminals of cholecystokinin (CCK)-expressing GABAergic 
interneurons from the CA1 and CA3 subfields (Katona et al., 1999; 
Hájos et al., 2000). An important physiological mechanism of short-
term synaptic plasticity that depends on the regulation of GABA from 
these interneurons (depolarization-induced suppression of inhibition, 
DSI, detailed in Figure 1.1.5a) was first described in the early 1990’s 
(see Alger, 2002), but its regulation was attributed to an unidentified 
substance (Llano et al., 1991; Pitler and Alger, 1992). It was later 
found that postsynaptically derived endocannabinoids, released on-
demand, mediate this phenomenon in a phasic (Ohno-Shosaku et 
al., 2001; Wilson and Nicoll, 2001), and tonic (Neu et al., 2007) 
manner. Kreitzer and Regehr (2001) showed that endocannabinoids 
mediate depolarization-induced suppression of excitation (DSE, 
detailed in Figure 1.1.5b) and a recent study has identified 2-AG as 
the endocannabinoid which regulates DSI and DSE in the 
hippocampus, cerebellum and striatum (Tanimura et al., 2010). 
Furthermore, an endocannabinoid-mediated form of long-term 
synaptic plasticity (long-term depression) was recently characterized 
(for a review, see Heifets and Castillo, 2009). 
 The expression of CB1 receptors at glutamatergic neurons is 
approximately 20 times lower than at GABAergic neurons (Katona et 
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al., 2006; Kawamura et al., 2006; Mackie and Katona, 2009) and the 
role of CB1 receptors at these neurons is believed to be mostly of a 
‘synaptic circuit breaker’ (Katona and Freund, 2008). This concept 
stems from the key modulatory role that is played by 2-AG in 
situations of extreme activity in presynaptic glutamatergic terminals. 
An excessive release of glutamate can trigger postsynaptic 2-AG 
release, through a mechanism involving the activation of group I 
metabotropic glutamate receptors (mainly mGluR5). Acting 
retrogradely, 2-AG can then activate presynaptic CB1 receptors to 
inhibit the release of glutamate (see Katona and Freund, 2008). This 
mechanism has a neuroprotective role that appears to be critical in 
epileptogenic circuits (Domenici et al., 2006; Monory et al., 2006).  
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 
Figure 1.1.5. Schematic diagram summarizing the mechanisms of 
endocannabinoid-mediated short-term depression: DSI (1) and DSE 
(2). (1) DSI is mainly triggered by a depolarization-induced Ca2+ influx 
through postsynaptic VGCCs. The rise in intracellular Ca2+ triggers 2-AG 
release through a yet unidentified mechanism, and this effect can be 
amplified by Ca2+ released from intracellular stores. (2) DSE is mainly 
triggered by the depolarization of excitatory afferents and by group I 
metabotropic glutamate receptor (mGlu1R) activation. Activation of PLC is 
triggered by mGlu1R activation, and it can be facilitated by the rise in 
intracellular Ca2+. This then leads to the production of 2-AG via DGL (see 
Figure 1.1.2b). AMPA receptor (AMPAR) activation may also contribute to 
this mechanism. 2-AG then diffuses across the membrane to act 
retrogradely by activating presynaptic CB1 receptors (CB1R), which results 
in Ca2+ channel inhibition, a direct effect on the exocytotic release 
machinery, and/or K+ channel activation (adapted from Chevaleyre et al., 
2006). 	  
 
 
1.1.3. Role of CB1 receptors in learning and memory 
 
 The cognitive disrupting effects of THC, and synthetic CB1 
receptor agonists, are well characterized in humans and animal 
models (Hampson and Deadwyler, 1999; Lichtman et al., 2002; 
Egerton et al., 2006; Ranganathan and D'Souza, 2006). Several 
A1-­‐CB1	  receptor	  interplay	  in	  the	  hippocampus	  
	  12	  
studies consistently indicate that the endocannabinoid system is 
particularly relevant for the regulation of hippocampal-dependent 
short-term memory, as evaluated in various testing paradigms, such 
as the delayed non-matching to sample (DNMS) test, the Morris 
water maze and the radial arm maze (e.g. Hampson and Deadwyler, 
2000; Varvel et al., 2001; Robinson et al., 2008; Goonawardena et 
al., 2009). It is also reported that chronic THC exposure leads to 
tolerance to its memory disruptive effects, by inducing adaptive 
changes in the hippocampus (Hampson et al., 2003).  
 In the hippocampus, CCK-expressing GABAergic interneurons 
regulate the temporal coordination in the activity of principal cell 
assemblies, in a CB1 dependent manner (Hájos et al., 2000; Robbe 
et al., 2006; Freund and Katona, 2007). This spike timing 
coordination is critical for the integrity of hippocampal-dependent 
memory (Robbe and Buzsáki, 2009). Accordingly, it was recently 
demonstrated that presynaptic CB1 receptors (Wise et al., 2009), at 
GABAergic, but not glutamatergic, neurons are required for the 
effects of THC on hippocampal-dependent memory (Puighermanal et 
al., 2009).  
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1.2. Adenosine 
 
 The nucleoside adenosine (Figure 1.2.1) is an elemental 
endogenous substance that has a fundamental role in the synthesis 
of nucleic acids, intracellular energy transfer, as ATP and ADP, and 
signal transduction, as cyclic AMP. 
 
 
   Figure 1.2.1. Chemical structure of adenosine. 
The nucleoside adenosine is composed of the 
purine adenine attached to a ribose sugar molecule. 
 
 
 
 Acting through cell surface receptors present throughout most 
body tissues, adenosine is an important modulator of various 
physiological functions, including: cardiovascular (Mullane and 
Williams, 1990), renal (Churchill and Bidani, 1990), respiratory 
(Griffiths and Holgate, 1990) and central nervous system (e.g., see  
Sebastião and Ribeiro, 2009b). Since adenosine is neither stored in 
synaptic vesicles, nor released by exocytosis, it is considered a 
neuromodulator (for a review, see Ribeiro et al., 2002). Adenosine 
receptors are also the main target of caffeine (Fredholm et al., 1999; 
Ribeiro and Sebastião, 2010), the most widely consumed 
psychoactive substance worldwide (Barone and Roberts, 1996), 
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which is present in various dietary sources, such as coffee, tea and 
soft drinks (Figure 1.2.4, section 1.2.3). 
 The actions of adenosine as a regulator of physiological function 
have been extensively studied since it was first described to have 
effects in the cardiovascular system (Drury and Szent-Gyorgyi, 
1929). Research into the modulatory role of adenosine in the nervous 
system began in the early 1970s (reviewed by Cunha, 2001). 
Currently, adenosine is recognized as a key neuromodulatory 
substance, regulating the release of all known neurotransmitters, and 
also regulating the actions of other modulators, such as bioactive 
peptides, neurotrophic factors, and cannabinoids (reviewed by 
Sebastião and Ribeiro, 2009b). 
 As Figure 2.1.2 illustrates, adenosine can be synthesized 
intracellularly by the dephosphorylation of adenosine 5’ phosphates 
(ATP, ADP, AMP) by 5’-nucleotidase, or by hydrolysis of S-
adenosylhomocysteine (Arch and Newsholme, 1978; Fredholm et al., 
2005b). Adenosine can also be generated extracellularly, by the 
rapid hydrolysis of nucleotides catalyzed by ectonucleotidases 
(Zimmermann, 2000). Moreover, extracellular adenosine 
concentrations are regulated by bi-directional equilibrative and Na+-
dependent concentrative nucleoside transporters (see e.g. Fredholm 
et al., 2005b).  
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 Figure 1.2.2. Scheme representing the intracellular and 
extracellular pathways of adenosine metabolism. Adenosine is 
synthesized intracellularly and extracellularly and extracellular adenosine 
concentrations are regulated by bi-directional equilibrative and Na+-
dependent concentrative nucleoside transporters.  
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 The extracellular levels of adenosine can be dramatically 
increased under hypoxic, hypoglycaemic, or ischemic conditions, and 
also, in the brain, under conditions of increased neuronal firing 
(reviewed by Cunha, 2001; Dunwiddie and Masino, 2001). 
Elimination of adenosine (see Figure 1.2.2) occurs primarily through 
the phosphorylation to AMP by intracellularly located adenosine 
kinase, or by degradation to inosine by intracellularly and 
extracellularly located adenosine deaminase (Dunwiddie and Masino, 
2001).  
 
 
1.2.1. Adenosine receptors 
 
 Four specific adenosine receptors have been cloned and 
characterized to date: A1, A2A, A2B, and A3, and all belong to the 
GPCR superfamily (Fredholm et al., 1994). The adenosine receptors 
initiate intracellular signalling mainly through the activation of 
inhibitory Gi/o proteins (A1, A3), or stimulatory Gs/Golf proteins (A2A, 
A2B) (see Table 1.2.1). The A1 and A2A receptors exhibit higher 
affinity for adenosine than A2B or A3, and are believed to be of 
greater physiological relevance in the brain (Dunwiddie and Masino, 
2001). However, despite having a very low density, the A3 receptor is 
also a high affinity receptor in the human CNS (see Ribeiro et al., 
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2002). The main adenosine receptor signal transduction effectors are 
shown in Table 1.2.1. 
 
 
Table 1.2.1. Adenosine receptors in the brain 
 
GIRKS, G-protein-dependent inwardly rectifying K+ channels; PLC, 
phospholipase C. From Boison (2005). 
 
 Adenosine receptors are among the most widely expressed in 
the brain (for a review, see Dunwiddie and Masino, 2001; Ribeiro et 
al., 2002). A1 receptors are the most abundantly expressed in the 
brain, with higher densities in the neocortex, hippocampus, 
cerebellum and spinal cord (see Figure 1.2.3). On the other hand, 
A2A receptors are more abundant in the basal ganglia and olfactory 
bulb, with low expression in other brain areas (Figure 1.2.3).  
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Figure 1.2.3. Distribution and levels of adenosine receptor expression 
in the brain. Note that A1 receptors are highly expressed in the cortex, 
hippocampus and cerebellum, while A2A receptors are predominant in the 
striatal areas and olfactory bulb (from Ribeiro et al., 2002). 
 
 
 
 Although A2A receptors are present in much lower density in the 
hippocampus (Cunha et al., 1994b; Cunha et al., 1996b), they can be 
preferentially activated by extracellularly generated adenosine to 
facilitate neurotransmitter release (Cunha et al., 1996a). Notably, 
some hippocampal A2A receptors are coupled to inhibitory Gi/o 
proteins (Cunha et al., 1999). The A2B and A3 receptors have a very 
low density in the brain and their physiological roles are poorly 
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characterized. Adenosine predominantly maintains an inhibitory 
tonus in the brain, due to the prevalence of A1 receptors (Dunwiddie 
and Masino, 2001).  
 Both A1 and A2A receptors are predominantly, but not exclusively, 
located presynaptically (e.g. Rebola et al., 2003; Rebola et al., 
2005a; Rebola et al., 2005b). Previous evidence indicates that A1 
and A2A receptors may be co-localized in the same nerve terminals 
(e.g. Correia-de-Sa et al., 1991; Lopes et al., 1999; Rebola et al., 
2005b; Pousinha et al., 2010). Moreover, both receptors were shown 
to form a heteromeric complex in co-transfected cultured cells 
(Ciruela et al., 2006). It is believed that A1 or A2A receptors are 
preferentially activated as a function of the source and amount of 
adenosine (for a review, see Sebastião and Ribeiro, 2009b). A1 
receptors are preferentially activated by adenosine generated 
intracellularly, released through adenosine transporters, and A2A 
receptors are activated preferentially by adenosine generated 
extracellularly (Cunha et al., 1996a), due to the action of 
ectonucleotidases upon released ATP. 
 
 
1.2.2. Adenosine A1 receptor signalling and function in the 
hippocampus 
 
 Most of the actions of adenosine in the brain involve the inhibitory 
modulation of presynaptic neurotransmitter release (Dunwiddie and 
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Masino, 2001). A1 receptors mostly affect excitatory synaptic 
transmission (e.g. Dunwiddie and Fredholm, 1989; Sebastião et al., 
1990; de Mendonça and Ribeiro, 1993), having no direct influence 
upon GABAergic transmission in mature hippocampal neurons 
(Lambert and Teyler, 1991; Yoon and Rothman, 1991; Li and Henry, 
2000) or on GABA release from isolated nerve terminals (Cunha and 
Ribeiro, 2000). However, A1 receptors in GABAergic neurons may 
have a role during development (Jeong et al., 2003) and remain 
present in adult hippocampal GABAergic interneurons (Ochiishi et 
al., 1999), where they control the actions of the peptide modulator 
vasoactive intestinal peptide (Cunha-Reis et al., 2008).  
 Accordingly, adenosine, through activation of A1 receptors 
modulates long-term potentiation (LTP) and long-term depression 
(LTD, Arai et al., 1990; de Mendonça and Ribeiro, 1994, 1997). 
Additionally, it has a pivotal neuroprotective role in hypoxic conditions 
(de Mendonça et al., 2000), and has been coined the ‘brain’s 
endogenous anti-convulsant’ due to its inhibitory role in epileptogenic 
circuits (Boison, 2005).  
 
 
1.2.3. Role of adenosine receptors in learning and memory 
 
 The importance of adenosine for the modulation of LTP in the 
hippocampus suggests an involvement of adenosine receptors in the 
function of memory. There are several conflicting reports concerning 
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the involvement of A1 receptors in learning and memory (see e.g. 
Takahashi et al., 2008). Most of the findings in the literature derive 
from studies of the effects of caffeine (Figure 1.2.4), which, at 
moderate doses, is an adenosine A1 and A2A receptor antagonist with 
cognitive enhancing properties (reviewed by Daly and Fredholm, 
1998; Fredholm et al., 1999; Nehlig, 2010).  
 
 
Figure 1.2.4. Chemical structure of caffeine. 
Caffeine is a xanthine alkaloid and it was first 
identified in 1819 by the german chemist Friedrich 
Runge (Weinberg and Bealer, 2001). 
 
 
 Evidence shows that acute administration of low to moderate 
doses of caffeine (0.3-3 mg/kg) improves spatial memory retention 
and consolidation (e.g. Angelucci et al., 1999; Kopf et al., 1999; 
Angelucci et al., 2002), while higher doses may disrupt spatial 
memory acquisition (Kant, 1993). Moreover, acute caffeine appears 
to affect particular stages of memory processing, according to time of 
administration in the testing paradigm (Angelucci et al., 1999; 
Angelucci et al., 2002). Studies of caffeine and memory in human 
subjects suggest that caffeine has a limited cognitive enhancing 
effect on working memory and long-term memory, and its effects 
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appear to be mostly related to its perceptual-motor stimulatory 
properties (reviewed by Nehlig, 2010). 
 According to animal studies using receptor subtype-specific 
antagonists, there is some controversy as to whether A1 (Normile and 
Barraco, 1991; Hooper et al., 1996; Ohno and Watanabe, 1996; 
Pitsikas and Borsini, 1997; Pereira et al., 2002), A2A (Kopf et al., 
1999), or both receptors (Pereira et al., 2005; Prediger et al., 2005; 
Prediger and Takahashi, 2005) are preferentially involved in 
hippocampal-dependent memory function. However, it is difficult to 
interpret these findings, as they derive from various memory testing 
paradigms, using different rodent species, doses and administration 
methods.  
 Adenosine A1 receptor knockout mice exhibit normal spatial 
reference and working memory (Giménez-Llort et al., 2002; 
Giménez-Llort et al., 2005), but show a mildly increased anxiety 
response to the water-maze environment (Lang et al., 2003). The 
contrast between data derived from A1 receptor knockout mice and 
from the administration of specific A1 receptor antagonists indicates 
that the A1 receptor knockout mice possess adaptive mechanisms to 
overcome the adenosinergic control of memory function.  
 Since A2A receptors are highly expressed in the dorsal and 
ventral striatum, studies using A2A receptor knockout mice have 
mainly focused on the role of these receptors in motor function (for a 
review, see Fredholm et al., 2005a; Fredholm et al., 2005b). Indeed, 
specific A2A receptor antagonists, or caffeine, have motor stimulating 
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effects in wild type mice, but caffeine is a motor depressant in A2A 
receptor knockouts (Fredholm et al., 2005b). The general consensus 
is that A2A receptors are particularly involved in the stimulatory 
effects of moderate doses of caffeine, although they are also 
involved in working memory performance (reviewed by Chen et al., 
2010). However, given the prevalence of A1 receptors in the 
hippocampus and cortex, one hypothesis suggested by Takahashi et 
al. (2008) is that acute caffeine, at moderate doses, improves some 
aspects of memory due to a preferential blockade of A1 receptors. 
 On the other hand, chronic administration of caffeine, or other 
adenosine receptor antagonists, is generally reported to have no 
effect upon spatial memory (see Jacobson et al., 1996; Takahashi et 
al., 2008), while chronic exposure to A1 receptor agonists improves 
memory (Von Lubitz et al., 1993). Such differences are believed to 
be a result of chronic caffeine-induced adaptive changes in the levels 
of A1, but not A2A receptors (Jacobson et al., 1996), which may 
interfere with the endogenous adenosinergic tone. Interestingly, 
chronic caffeine is also linked to increased behavioural effects of 
some psychostimulants, such as nicotine, metamphetamine and 
cocaine (Gasior et al., 2000; Justinova et al., 2009), where A1 
receptors seem to be particularly involved. These findings suggest 
that adaptive changes, which occur in the brain following chronic 
caffeine exposure, carry relevant implications for the pharmacology 
of psychoactive drugs. 
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1.3. Adenosine and cannabinoid receptor interactions 
 
 As it has been described above, there are many similarities in the 
physiological and functional characteristics of both A1 and CB1 
receptors. Both receptors negatively modulate synaptic transmission 
through activation of G-protein αi/o subunits (Straiker et al., 2002), 
which inhibit adenylyl cyclase, block voltage-gated calcium channels 
(VGCCs) and activate inwardly rectifying potassium channels 
(Dunwiddie and Masino, 2001; Howlett, 2005). At the functional level, 
the coincident brain areas, in which both receptors share a high 
density of expression, result in similar physiological roles, mainly in 
the regulation of cognitive and motor function.  
 Several studies indicate that A1 and CB1 receptors have a 
functional interplay in various brain areas. In the cerebellum, A1 
receptors modulate the motor incoordination effects induced by acute 
administration of THC or CB1 receptor agonist CP55,940 (Dar, 2000; 
DeSanty and Dar, 2001; Dar and Mustafa, 2002). Furthermore, 
prolonged intracerebellar administration of a CB1 agonist induced 
tolerance to the acute effects of an A1 receptor agonist (cross-
tolerance) and, conversely, prolonged treatment with an A1 receptor 
agonist induced tolerance to the acute effects of a CB1 agonist 
(DeSanty and Dar, 2001). Similar observations were obtained in two 
subsequent studies (Kouznetsova et al., 2002; Selley et al., 2004).  
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 A more recent study observed that CB1-mediated inhibition of 
excitatory synaptic transmission in the hippocampus is modulated by 
endogenous adenosine, through A1 receptor activation (Hoffman et 
al., 2010). However, Serpa et al. (2009) previously observed that 
there was an absence of CB1-A1 receptor cross-talk upon the 
Schaffer collateral / CA1 pyramidal cell pathway, suggesting that this 
interaction did not occur at the glutamatergic nerve terminals. The 
opposing results reported by Serpa et al. (2009) may be due to 
differences in the levels of endogenous adenosine in the slice 
perfusion chamber, since the effect of CB1 receptor agonist 
WIN55,212-2 was not altered in the presence of A1 receptor 
antagonist DPCPX. Differences in the slice preparation process and 
perfusion flow rate between the two studies could lead to altered 
levels of endogenous adenosine. In addition, the effect of A1 receptor 
agonist CPA was unaltered in the presence of WIN55,212-2, while 
the effect of WIN55,212-2 alone was not compared to its effect in the 
presence of CPA. This could have prevented the observation of an 
interaction if the cross-talk is unidirectionally regulated by A1 
receptors. In this case, the activation of A1 receptors could alter the 
response to CB1 receptor activation, while CB1 activation would not 
affect the response to A1 activation. 
 Functional interactions have also been observed between CB1 
and A2A receptors, which share a high level of expression in the 
striatum. The A2A receptors were found to be important for the 
rewarding effects of THC administration and the somatic effects of 
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THC withdrawal (Soria et al., 2004). Importantly, Carriba et al. (2007) 
demonstrated that A2A and CB1 form a heteromeric complex in co-
transfected HEK-293T cells and it has been shown that blockade of 
A2A receptors inhibit CB1 signalling on corticostriatal slices (Tebano 
et al., 2009), and also prevents the motor-depressant effects of CB1 
activation in vivo (Carriba et al., 2007). The phenomenon of receptor-
receptor interactions is physiologically relevant (Milligan, 2008) and 
presents very interesting prospects for the development of more 
target-specific pharmacological tools (Ferré et al., 2009).  
 The findings described above raised the intriguing hypothesis 
that a functional interaction between A1 and CB1 receptors in the 
hippocampus may have cognitive and pathophysiological 
implications, particularly for the effects of cannabis and caffeine 
consumption in humans. 
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2. Aims 
 
To investigate whether an A1-CB1 receptor interplay occurs in the 
hippocampus and to evaluate its functional consequences, using ex 
vivo, in vitro and in vivo approaches, I: 
 
a) measured the effects of A1 receptor ligands on the CB1-
mediated inhibition of GABA and glutamate release, and 
examined whether this interaction is manifested at the level of 
G-protein activation. 
 
b) evaluated the influence of chronic caffeine administration, 
and the involvement of A1 receptors, on the spatial memory 
deficits induced by acute THC administration in vivo, by using 
a hippocampal-dependent short-term spatial memory testing 
paradigm. 
 
c) studied the effects of chronic caffeine administration upon 
the levels of cortical and hippocampal A1 and CB1 receptors, 
and upon CB1 receptor signalling, by measuring GABA 
release and CB1 receptor ligand-stimulated G-protein 
activation in cortico-hippocampal membranes. 
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3. Materials and methods 
3.1. Subjects 
 
 Two species of rodents widely used as model organisms in 
neuroscience research, were the subjects in this thesis: the Wistar 
rat (Rattus norvegicus, 6-8 weeks old) and the C57Bl/6J mouse (Mus 
Musculus, wild type, 12-16 weeks old), all of male gender. The 
experiments on chapter 4.1 were performed in Wistar rats, while the 
C57Bl/6J mice were used in all experiments on chapters 4.2 and 4.3. 
Despite yielding larger amounts of biological sample for 
neurochemical assays, using rats for chronic handling, daily 
injections and behavioural work has several practical disadvantages 
compared to using mice. The C57Bl/6J mouse has been extensively 
used in behavioural studies and the systemic effects of cannabinoids 
on motor and cognitive function have been previously studied (e.g. 
Varvel et al., 2001; Varvel and Lichtman, 2002; Varvel et al., 2005b; 
Varvel et al., 2005a; Mcmahon and Koek, 2007). Therefore, mice 
were chosen as the subjects for all the experiments involving chronic 
caffeine administration.  
 All animals were supplied by Harlan Laboratories (Spain, UK). 
Upon arrival at the animal facility, animals were group housed in a 
temperature and humidity regulated room with a 12h dark/light cycle 
(lights on at 06:00 h), and free access to food and water. Before any 
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in vivo experimentation, subjects were allowed a period of 5 days in 
order to familiarize with the animal facility. Experiments were 
performed during the light phase. All experimentation followed the 
UK Animals (Scientific Procedures) Act, 1986, Portuguese and EU 
law concerning animal care. All efforts were made to minimize animal 
suffering and the number of animals used.  
 
 
3.2. Drugs and antibodies 
 
 4-amino-[2,3-3H]butyric acid ([3H]GABA), L-[G-3H]glutamic 
acid ([3H]glutamate), [3H]DPCPX, and [3H]SR141716A were obtained 
from GE Healthcare Life Sciences (Buckinghamshire, UK). 
Guanosine 5’-(γ-[35S]-thio) Triphosphate, ([35S]-GTPγS) was from 
Perkin Elmer NEN Radiochemicals (Boston, MA, USA). Adenosine 
deaminase (ADA, EC 3.5.4.4) was from Roche Diagnostics 
(Indianapolis, IN. USA). ∆9-Tetrahydrocannabinol (THC, >98% purity) 
was from THC Pharm (Frankfurt, Germany). CdCl2, caffeine 
(anhydrous base), GABA, aminooxyacetic acid (AOAA), guanosine 
diphosphate (GDP), guanosine 5'-O-[gamma-thio]triphosphate 
(GTPγS) were from Sigma (St Louis, MO, USA). 1-(4,4-diphenyl-3-
butenyl)-3-piperidinecarboxylic acid hydrochloride (SKF89976A), N6-
cyclopentyladenosine (CPA), 8-cyclopentyl-1,3-dipropylxanthine 
(DPCPX), 8-[4-[(2-Aminoethyl) amino]carbonylmethyloxyphenyl] 
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xanthine (XAC), ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
naphthalenyl-methanone mesylate (WIN55,212-2), ([(3S)-2,3-
Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-
benzoxazin-6-yl]-1-naphthalenyl-methanone monomethanesulfonate 
(WIN55,212-3), and N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251), were 
from Tocris  Bioscience (Bristol, UK). ((RS)-4-Amino-3-(4-
chlorophenyl)butanoic acid (baclofen) was from Ascent Scientific 
(Bristol, UK). All other reagents were from Sigma.  
 For in vitro experiments, non-water soluble drugs were dissolved 
in dimethyl sulfoxide (DMSO), aliquoted and stored at -20º C. The 
amount of DMSO in solutions was normalized for all conditions in any 
given experiment, and always <0.02%.  
 Rabbit anti-CB1 antibody (L15) was a generous gift of Prof. Ken 
Mackie (Indiana University, IN, USA). The rabbit anti-tubulin and the 
HRP-coupled anti-rabbit secondary raised in goat were from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). 
 
3.2.1. in vivo drug administration 
 
3.2.1.1. Behavioural experiments 
 Mice were randomly assigned to various groups and 
habituated to the manipulation and injection procedures during 5 
days before testing began. For chronic treatment with caffeine, 
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animals received caffeine (3 mg/kg/day), or vehicle (Saline: 0.9% 
NaCl), for at least 15 days prior to experimental days, and throughout 
the course of behavioral testing, in order to avoid withdrawal effects. 
To prevent effects on memory consolidation (Angelucci et al., 2002), 
caffeine was given 2 h after animals finished their last water maze 
trials of the day. The half-life of caffeine for doses lower than 10 
mg/kg ranges from 0.7 to 1.2 h in the rat and mouse (Fredholm et al., 
1999), therefore the estimated concentrations of caffeine present in 
plasma or brain during behavioral testing (i.e. at least 12 h later) 
were negligible.  
 For acute administration, animals received a single dose of vehicle 
(8% Tween 80 in saline), THC (1 to 7 mg/kg), AM251 (3 mg/kg), 
DPCPX (1 mg/kg), or WIN55,212-2 (1 mg/kg). THC was prepared 
according to a method described by Pertwee et al. (1992), as follows: 
An ethanolic THC solution (31.5 mg/ml) was mixed with 2 parts of 
Tween 80 by weight. The ethanol was removed by evaporation, and 
then saline (0.9% NaCl) was added to form a 1 ml dispersion 
containing the drug. To ensure that the dispersion would be 
homogeneous, the saline was added in a series of aliquots of 
increasing volume (50 µl x 2, 100 µl x 2, 200 µl and 500 µl), the 
mixture being shaken between additions with a vortex mixer. 
Dilutions were made serially, and each dilution step involved the 
mixture of 1 volume of dispersion with up to 9 volumes of saline. As 
in the vehicle solution used to dilute AM251, DPCPX and 
WIN55,212-2, the final concentration of Tween 80 was 8% v/v, which 
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was previously shown not to affect motor activity in mice (Castro et 
al., 1995). 
 AM251, DPCPX, and WIN55,212-2 were suspended in the vehicle 
and carefully sonicated. All drugs were given by intraperitoneal 
injection (i.p.) in a volume of 2 ml/kg weight. Drug and vehicle 
solutions were aliquoted in the final concentrations and stored at -
20ºC, to be thawed only in the day of use. 
 The drug administration and testing schedules are described in 
section 3.7.2., and shown in Figures 3.7.3. to 3.7.5. Total caffeine 
exposure was for 22-24 days, after which subjects were euthanized 
by cervical dislocation, 24 h subsequent to the last injection. The 
hippocampi and cortices were then immediately dissected and stored 
at -80ºC for later analysis. 
 
 
 3.2.1.2. Neurochemical experiments 
 Mice were first handled and habituated for 5 days prior to first 
injection, then subjects were randomly divided into a control group, 
receiving saline, and a chronic caffeine group. Caffeine was 
dissolved in a 0.9% NaCl vehicle solution and was given chronically 
(3 mg/kg/day, i.p.) during 22-24 days. Animals were euthanized by 
cervical dislocation 24 h after the last caffeine injection. For 
neurotransmitter release assays, cortico-hippocampal synaptosomes 
were freshly prepared after dissection, while cortico-hippocampal, 
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striatal and cerebellar samples to be used in binding assays or 
Western blotting were stored at -80ºC for later analysis. 
 
 
 
 
3.3. Sample preparations 
 
 
3.3.1. Synaptosomes 
 
 Synaptosomes are presynaptic nerve terminals with sealed 
membranes that are detached (pinched-off) from their axon by the 
shearing action of tissue homogenization, and can be isolated as a 
purified subcellular fraction from a sucrose homogenate by 
centrifugation (Gray and Whittaker, 1962). Under metabolizing 
conditions, synaptosomes respire, take up oxygen and glucose, 
maintain normal membrane potential and release neurotransmitters 
in a Ca2+-dependent manner when depolarized (reviewed by 
Whittaker, 1993). Thus, a synaptosome is a well-organized 
cytoplasmic unit that retains the essential biochemical and 
morphological characteristics of the original presynaptic terminal 
(Bradford et al., 1973). 
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 Since they were first isolated by Hebb and Whittaker (1958), 
synaptosomes have been extensively used as a model for studying 
the synapse, as they contain all elements necessary for the 
presynaptic function of neurotransmitter uptake, storage and release, 
and thus represent the simplest system for the study of 
depolarization-induced transmitter release (Nicholls, 1989). Although 
brain slice preparations are also an important model in 
neurochemical research, the complex nature of the neuronal circuits 
involved in signalling limit its usefulness in the investigation of the 
molecular mechanisms of Ca2+-dependent neurotransmitter release. 
 Synaptosomes were prepared from rat hippocampi (2 rats) or 
mouse cortico-hippocampal tissue (both hemispheres, from 1 mouse) 
according to a previously validated procedure (e.g. Assaife-Lopes et 
al., 2010), with some modifications. Animals were decapitated under 
halothane anaesthesia and the tissue was dissected in a 
continuously oxygenated (95% O2, 5% CO2) ice cold artificial 
cerebrospinal fluid (aCSF) of the following composition (mM): NaCl 
125, KCl 3, NaH2PO4 1, NaHCO3 25, CaCl2 1.5, MgSO4 1.2, glucose 
10, pH 7.4. Samples were homogenized with a motor-driven (1500 
rpm) Teflon-glass homogenizer in 15 ml of an ice cold 0.32 M 
sucrose solution containing 1 mM EDTA and 10 mM HEPES, pH 7.4. 
The homogenate was then centrifuged at 3000 g for 10 min, 4ºC, and 
the supernatant obtained was centrifuged at 14000 g for 12 min, 4ºC, 
to obtain a stratified pellet (Figure 3.3.1.). This pellet is composed of 
a compact buff-coloured layer of mitochondria that does not show 
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detectable Ca2+-dependent neurotransmitter release underlying a 
whiter loosely compacted layer containing the majority of the 
synaptosomes (McMahon et al., 1992; Phelan and Gordon-Weeks, 
1997).  
 Protein content of the pellet was determined by the Bradford 
method (Bradford, 1976), using bovine serum albumin (BSA) as a 
standard. The pellet obtained from a preparation of 4 hippocampi 
contains 7.5 ± 0.5 mg of protein (n=5).  
 
 
 
 
 Figure 3.3.1. Schematic diagram outlining the main steps in the 
preparation of synaptosomal and membranar fractions from brain 
tissue. The brain tissue is homogenized in a 0.32 M sucrose solution then 
fractionation is performed by a first centrifugation from which the precipitate 
containing most of the cellular debris (P1) is discarded; the supernatant is 
then centrifuged again at a higher speed, and the resulting supernatant 
(S2) is discarded, leaving a precipitate containing the fraction of interest 
(P2). See text for further details. 
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3.3.2. Cell membrane fractions 
 
 Cell plasma membranes can be isolated by fractionation of brain 
tissue homogenates to provide a sample that is effective for the 
pharmacological analysis of G-protein coupled receptor function and 
ligand binding properties.  
 Rat hippocampal, or mouse cortico-hippocampal membranes were 
prepared essentially as previously described (e.g. Cunha et al., 
1999), with modifications. Animals were decapitated under halothane 
anaesthesia and the tissue was dissected in a continuously 
oxygenated (95% O2, 5% CO2) ice cold artificial cerebrospinal fluid 
(aCSF) of the following composition (mM): NaCl 125, KCl 3, 
NaH2PO4 1, NaHCO3 25, CaCl2 1.5, MgSO4 1.2, glucose 10, pH 7.4. 
Tissue, from each subject was homogenized with a motor-driven 
(1500 rpm) Teflon-glass homogenizer in 15 ml of ice-cold 0.32 M 
sucrose solution containing 2 mM EGTA, 1 mM DTT and 50 mM Tris, 
pH 7.6. The homogenate was centrifuged at 1000 g for 10min, 4ºC, 
and the supernatant obtained was centrifuged at 14000 g for 12 min, 
4ºC to obtain a pellet containing the membrane fraction (Figure 
3.3.1.). 
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3.4. Neurotransmitter release assays 
 
  There are various useful ex vivo methods to analyze the effects of 
drugs on the mechanisms of neurotransmitter release, however the 
assays utilizing tritium-labelled neurotransmitters are perhaps the 
most commonly used. It was first observed by Dengler et al. (1961) 
that brain slices take up [3H]Noradrenaline, and, in a later study, an 
electrical stimulation was used to evoke the release of 
[3H]Noradrenaline from brain slices under perfusion (Baldessarini 
and Kopin, 1966). However, the use of brain slices to study evoked 
neurotransmitter release has limited applications due to the difficulty 
in preventing the post-synaptic and circuit-level effects.  
 Since the metabolic properties of synaptosomes (Bradford, 1969; 
Bradford and Thomas, 1969) and their ability to depolarize upon an 
electrical stimulation or a high [K+] (Bradford, 1970) were originally 
described, it became increasingly clear that synaptosomes are an 
ideal model with which to study the mechanisms of presynaptic 
neurotransmitter release (Kauppinen and Nicholls, 1986; Nicholls, 
1989).  
 Using synaptosomes, it is possible to study the release of either 
endogenous or radiolabelled neurotransmitters. Endogenous 
neurotransmitter release assays, using synaptosomal homogenates 
in ‘batch’, also allow for the study of membrane transporters and 
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assessment of several bioenergetic parameters that affect 
neurotransmission by fluorimetric techniques (reviewed by Nicholls, 
1989). However, this approach does not prevent the accumulation of 
endogenous substances in the homogenate, which may introduce 
confounding effects in the response of the synaptosomes. 
  A method for applying depolarizing stimuli to synaptosomal beds 
in superfusion was first described by de Belleroche and Bradford 
(1972), using an apparatus originally conceived by Henry McIlwain 
(McIlwain and Jones, 1970) to be used with brain slices. However, an 
improved method was later developed by Raiteri and Levi (1974), 
which prevented neurotransmitter re-uptake and enabled the analysis 
of several small samples in parallel. Continuous vertical superfusion 
of the synaptosomal layer not only prevents neurotransmitter re-
uptake but it also removes endogenous substances thus preventing 
confounding effects in the study of a given target. Therefore, the 
advantage of this method is its considerable target specificity in the 
approach to studying a drug or mechanism of interest (for a review, 
see Raiteri and Raiteri, 2000). The tritium-labelled neurotransmitter 
release assay procedure used in this thesis is adapted from the 
original (Raiteri et al., 1974), with some modifications (Cunha et al., 
1994a; Assaife-Lopes et al., 2010, present thesis).  
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3.4.1. [3H]GABA 
 
 The synaptosomal pellet (see section 3.3.1) was resuspended in 
aCSF and synaptosomes were incubated for 20 min, at 37º C, with 
1.5 µCi/ml [3H]GABA (1.85 nM), and 0.625 µM of unlabelled GABA to 
decrease specific activity of [3H]GABA to 2.3 µCi/nmol (see Figure 
3.4.1.a). Incubation and superfusion solutions consisted of 
oxygenated aCSF containing 0.1 mM of the GABA transaminase 
inhibitor aminooxyacetic acid (AOAA). Synaptosomes were then 
layered over GF/C filters (Millipore, MA, USA) on an 8-chamber 
superfusion apparatus (Raiteri et al., 1974), and superfused at a flow 
rate of 0.8 ml/min. This constant and rapid flow rate washes out 
endogenously released substances thus avoiding cross-influences 
between adjacent synaptosomes (see Raiteri and Raiteri, 2000). 
Samples were superfused for a period of 30 min to wash all unbound 
tritium and allow for stabilization of the samples (washout period).  
 In each experiment, the eluent was collected in 2 min fractions for 
a period of 36 min, with the application of two depolarizing stimuli to 
evoke neurotransmitter release. Stimuli were applied for 2 min with 
15 mM K+ (isomolar substitution of Na+ with K+) at the 6th (S1) and 
24th (S2) minutes of collection time (Figure 3.4.1.b). Drugs were 
added to the superfusion medium 6 min before S2, when testing for 
effects on S2.  
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 Test drugs were added to the superfusion medium from the 18th 
minute onward, to measure effects on S2. In order to assess the 
ability of a ligand to modify the effect of a drug applied before S2, the 
ligand was added from the 15th minute of the washout period onward, 
i.e. it was present during S1 and S2. Each condition was tested in 
duplicate, as commonly accepted in this paradigm (e.g. Cunha and 
Ribeiro, 2000).	  At the end of each experiment, sample fractions and 
filters were analyzed by scintillation assay. Filter content was 
quantified for determination of the remaining tritium retained in the 
synaptosomes. Under similar conditions, the percentage of GABA 
and glutamate in the K+-evoked outflow is >90% of the total tritium in 
the sample (Cunha et al., 1997; Lopes et al., 2002).  
 Fractional [3H]neurotransmitter release was expressed as the 
percentage of total radioactivity present in the synaptosomes at the 
time of collection of each sample (FR%). The amount of tritium 
released after each pulse of K+ (S1 or S2) was calculated by 
integration of the peak area. Effects were calculated by normalizing 
the S2/S1 values of corresponding controls from the same batch of 
synaptosomes to 0% effect. For example, the effect of WIN55,212-2 
(added before S2), in the presence of CPA (during S1 and S2), was 
calculated using the S2/S1 of CPA alone (during S1 and S2) as a 
control, which was obtained from the same experiment and batch of 
synaptosomes. 
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 Figure 3.4.1. The [3H]-neurotransmitter release procedure. (a) 
schematic diagram of the experimental procedure: after resuspension, 
synaptosomes are incubated with the [3H]-neurotransmitter, then layered 
over microporous filters inside each of the 8 superfusion chambers; 
subsequently, synaptosomes are continually superfused, at a flow rate of 
0.8 ml/min, with the appropriate superfusion solution (at 37ºC); after a 
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washout period samples are collected in fractions of 2 min for 36 min. The 
vertical superfusion of the synaptosomes washes away endogenous 
transmitters and other modulators before they activate their target receptor 
and before reuptake occurs. The effects of the drugs applied on the 
neurotransmitter of interest can therefore be mostly attributed to the direct 
actions of these drugs at the terminals storing that transmitter (Raiteri and 
Raiteri, 2000). (b) diagram representative of a K+-evoked 
[3H]neurotransmitter fractional release experiment. Transmitter release is 
evoked by two 15 mM K+ stimuli of 2 min duration, as indicated (S1 and S2); 
drug A is superfused 6 min before S2, to test for effects on S2; drug B is 
superfused 15 min before start of collection and remains throughout the 
experiment (S1+S2) to measure its influence in the effect of drug A. In this 
example, drug A inhibits the evoked transmitter release and this effect is 
prevented in the presence of drug B (throughout experiment), which by 
itself does not alter the S2/S1. See text for further details. 
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3.4.2. [3H]glutamate 
 
 The procedure for [3H]glutamate release was the same as for 
[3H]GABA release, with some exceptions: The synaptosomal pellet 
was resuspended in aCSF which did not contain AOAA, and 
synaptosomes were incubated for 5 min, at 37ºC, with 10 µCi/ml 
[3H]glutamate; additionally, the washout period was of 20 minutes. All 
remaining steps of the procedure were unchanged. 
 
 
3.5. Binding assays 
 
3.5.1. [3H]-ligand binding 
 
 A radioligand is a radioactive isotope-labelled drug that can 
associate with a receptor, transporter, enzyme or any protein of 
interest (reviewed by Motulsky and Neubig, 1997). The measurement 
of the ligand binding properties of GPCRs provides information on 
the number of binding sites and their affinity for various drugs. In 
addition, radioligand binding is (together with quantitative 
immunochemical assays) one of the only techniques that can 
determine the concentrations of receptors in tissue. This is optimally 
achieved by conducting these assays in preparations of cellular 
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membrane fractions. These assays were originally developed for 
studying polypeptide hormone receptors (Lefkowitz et al., 1970) but 
soon became a fundamental technique in the study of 
neurotransmitter receptor pharmacology (see Yamamura et al., 
1990). The advantage of this method is that it allows the 
determination of the initial interaction of the ligand with the 
transmembranar receptor, which is useful for direct characterization 
of receptor sites without interference of the subsequent steps that 
mediate the biological response.  
 There are two general classes of radioligand-receptor binding 
assays: equilibrium and non-equilibrium (see Basile, 1997). In the 
non-equilibrium binding assays (e.g. association and dissociation 
assays), the amount of ligand bound to a receptor is determined as a 
function of time, which is useful to measure the kinetics of ligand-
receptor interactions. In the equilibrium binding assays (e.g. 
competition and saturation assays), the amount of ligand bound to a 
receptor has reached steady-state levels for a given concentration of 
ligand and receptor. This class of assay allows, among other things, 
to measure receptor number and affinity.  
 While competition assays measure the binding of a single 
concentration of radioligand in the presence of various 
concentrations of unlabelled ligand, saturation assays determine the 
specific binding of increasing concentrations of a radioligand to a 
fixed amount of receptor. Thus, the amount of radioligand specifically 
bound to the receptor increases with the radioligand concentration, 
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until it asymptotically approaches a maximum level of binding (Bmax). 
Since a radioligand will also bind to sites other than the receptor, 
specific binding is calculated by subtracting nonspecific binding from 
the total radioligand binding at equilibrium (Figure 3.5.1.). The 
nonspecific binding increases linearly with increasing concentration 
and its levels are obtained by incubating each concentration of 
radioligand in the presence of a high concentration of unlabelled 
ligand.  
 Analysis of a saturation binding assay allows the determination of 
the maximum density of receptors available to the radioligand (Bmax), 
and the equilibrium dissociation constant (Kd), which is a measure of 
affinity expressed as the concentration of ligand that occupies half of 
the receptors at equilibrium. The Kd is calculated by the following 
equation:  
 
 
 
 
where koff is the dissociation rate constant (in units of min-1) and kon is 
the association rate constant (in units of M-1 min-1). 
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 Figure 3.5.1. Example of a saturation binding experiment. The 
specific binding (dashed curve) is calculated by subtracting the nonspecific 
binding from the total binding. The specific binding curve represents a 
nonlinear regression fitting of the values obtained from increasing 
concentrations of radioligand. Taken from Motulsky and Neubig (1997). 
 
 Bmax and Kd are accurately obtained by fitting a curve to the data, 
using nonlinear regression. Alternatively, the data can be linearized 
in a Scatchard-Rosenthal plot (Scatchard, 1949; Rosenthal, 1967), 
by plotting the amount of bound radioligand versus the ratio of bound 
to free radioligand. However, this does not provide a measurement 
as accurate as the non-linear regression since linear transformation 
of the data distorts experimental error, giving only approximate 
results (Motulsky and Neubig, 1997). 
 In this thesis, saturation binding assays were used to measure A1 
and CB1 receptor number and affinity, as follows. 
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• [3H]DPCPX 
The membrane pellets (see section 3.3.2) were resuspended in 
assay buffer (composition, in mM: Tris 50, MgCl2 2. pH = 7.4) and 
incubated with 4 U/ml ADA for 30 min at 37ºC, followed by 
centrifugation at 14000 g for 12 min. Protein content was determined 
by the Bradford method (Bradford, 1976), using BSA as a standard, 
then membranes (40 µg protein) were incubated for 1h at room 
temperature, in a final incubation volume of 300µl containing 4U/ml 
adenosine deaminase, in the absence and in the presence of 2 µM of 
XAC to measure non-specific binding (Figure 3.5.2.).  
 
• [3H]SR141716A 
The membrane pellets (see section 3.3.2) were resuspended in 
assay buffer (composition, in mM: Tris 50, MgCl2 2. pH = 7.4) and 
incubated with 4 U/ml ADA for 30 min at 37ºC, followed by 
centrifugation at 14000 g for 12 min. Protein content was determined 
by the Bradford method (as above), then membranes (50 µg protein) 
were incubated for 1h at 30° C, in a final volume of 300 µl containing 
1 mg/ml BSA, and using 1 µM of AM251 to measure non-specific 
binding (Figure 3.5.2.). 
 
 
 
 
 
Materials	  and	  methods	  
	   49	  
 
 Figure 3.5.2. Schematic diagram illustrating the main steps of the 
radiochemical binding procedure. In the radioligand binding 
experiments, increasing concentrations radioligand are added to the 
sample homogenate in absence (total) or presence of a high concentration 
of unlabelled ligand (nonspecific). In the [35S]GTPγS binding experiments, a 
fixed concentration of [35S]GTPγS and GDP is added to the sample 
homogenate aliquots containing increasing concentrations of unlabelled 
ligand in absence (total) or presence of a saturating concentration of 
unlabelled GTPγS (nonspecific). The samples are mixed and left to 
incubate and then submitted to vacuum filtration through glass fibre (GF) 
filters, followed by washing with ice-cold assay buffer. The unbound 
radiochemical is carried to a waste container and all bound radiochemical 
remains in the filters for subsequent determination of radioactivity by liquid 
scintillation.
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 Separation of bound and free radioligand was done by vacuum 
filtration of samples (Brandel cell harvester, Gaithersburg, MD, USA), 
through GF/C filters, followed by washing with ice cold assay buffer 
(Hall and Thor, 1979). To reduce non-specific binding of 
[3H]SR141716A, filters were soaked in 0.1% polyethylenimine for 
2.5h, at room temperature, before filtration and washing buffer 
contained 0.1mg/ml BSA (Hirst et al., 1996). Radioactivity was 
detected using a scintillation counter. 
 
 
3.5.2. [35S]-GTPγS binding 
 
 Although there are some examples of GPCRs that can trigger 
intracellular signalling independently of G proteins (see Brzostowski 
and Kimmel, 2001; Sun et al., 2007), the G proteins mainly function 
as the intermediaries in transmembrane signalling pathways initiated 
with GPCR activation, by conveying a chemical signal from the 
activated receptor to intracellular effectors (Gilman, 1987). 
 When occupied by their ligands, GPCRs become activated and 
directly bind to heterotrimeric G proteins, with subunits designated α, 
β and γ (Gilman, 1987). The binding of a G protein to the activated 
receptor initiates a number of steps that lead to downstream signal 
transduction events (reviewed by Lazareno, 1999; Milligan, 2003). 
The fist step is the guanine nucleotide exchange on the Gα subunit, 
where the dissociation of GDP from Gα allows the binding of 
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endogenous GTP in its place. GTP binding induces conformational 
rearrangements that lead to the dissociation of the G protein from the 
receptor and of Gα-GTP from Gβγ, each of which being able to 
activate effectors such as adenylyl cyclase, phospholipase C, and ion 
channels. Finally, hydrolysis of GTP to GDP induces the binding of 
Gα-GDP to Gβγ, thus inactivating the G protein. 
 
 
 
 
 Figure 3.5.3. Guanine nucleotide (GDP/GTP) exchange cycle. G-
proteins (αβγ) are stimulated by agonist (A) binding to receptor (high, RH, or 
low, RL, agonist affinity state), triggering the GDP/GTP exchange cycle, see 
text for details. Taken from Lazareno (1999). 
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 The guanine nucleotide exchange process can be monitored in 
vitro by measuring the binding of [35S]GTPγS, which is (unlike GTP) 
resistant to hydrolysis by GTPase and therefore accumulates in 
cellular membranes upon GPCR activation. This technique provides 
an excellent measure of the basic pharmacological characteristics 
and relative efficacy of drugs, as it targets the earliest event in the 
intracellular signal transduction cascade and is thus not susceptible 
to amplification or regulation by other cellular processes that occur 
downstream. Therefore, this technique was chosen to assess the 
efficacy and potency of a CB1 receptor agonists WIN55,212-2 and 
THC under various conditions. 
 The membrane pellets (see section 3.3.2) were resuspended in 
assay buffer (composition, in mM: Tris 50, MgCl2 5, NaCl 100, EGTA 
0.2, pH = 7.4) and incubated with 4 U/ml ADA for 30 min at 37ºC, 
followed by centrifugation at 14000 g for 12 min. Protein content was 
determined by the Bradford method (as above). Membranes (10 µg 
of protein) were then incubated with 0.1 nM [35S]-GTPγS and 0.1 nM-
10 µM of WIN55,212-2, or 0.1 nM-1 µM THC. For each of these 
agonists, the following assay conditions were tested in an assay 
buffer containing 30 µM GDP in a total volume of 500 µl, for 30 min 
at 37º C: 
a) no other drug added (control) 
b) co-application with 100 nM CPA 
c) co-application with 100 µM baclofen  
Materials	  and	  methods	  
	   53	  
At this GDP concentration, WIN55,212-2 has been shown to induce 
high affinity [35S]-GTPγS binding (Breivogel et al., 1998). Specific 
binding was calculated by subtracting nonspecific binding obtained 
by incubation with 10µM GTPγS.  
 The effect of co-application of CPA or Baclofen with WIN55,212-2, 
was calculated by subtracting the increase in [35S]-GTPγS induced by 
CPA or baclofen alone.  
 Each condition was tested in duplicates. Separation of bound and 
free radioligand was done by vacuum filtration of samples, through 
GF/C filters, followed by washing with ice-cold assay buffer (see 
Figure 3.5.2.). Radioactivity was detected using a scintillation 
counter.  
 
 
3.6. Electrophoresis and Western blotting 
 Samples were prepared from isolated mouse cortico-
hippocampal membranes (see section 3.3.2) by denaturing in 5x 
sample buffer (350 mM Tris, 30% glycerol, 10% SDS, 600 mM 
dithiothreitol, and 0.012% bromophenol blue, pH 6.80) and boiling for 
5 min. 20 µg per sample were loaded (total volume = 50 µl) into a 
15% SDS-Polyacrylamide gel mounted in an electrophoresis 
apparatus filled with running buffer (25 mM Tris, 192 mM glycine, 
0.1% SDS). Samples were stacked by running at 80 V and resolved 
at 150 V. Proteins were then transferred to a PVDF membrane 
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(permeabilized by soaking in methanol) for 2 h at 4ºC in transfer 
buffer (24 mM Tris, 182 mM glycine, 15% methanol). PVDF 
membranes were incubated with a blocking buffer (5% non-fat milk, 
TBS-T, 0.2 mM Tris, 137 mM NaCl, 0.1% Tween 20) for 1 h at room 
temperature. Membranes were incubated overnight at 4ºC with the 
primary antibodies (diluted in 3% BSA in TBS-T and 0.02% sodium 
azide). Membranes were then washed with TBS-T (4 x 10 min) and 
incubated for 1 h at room temperature with HRP-coupled secondary 
antibodies (diluted in blocking buffer, 1:15,000). After a final wash in 
TBS-T, detection of proteins was made using ECL plus western 
blotting detection. Optical density of the blots was quantified using 
the ImageJ software (NIH). The following primary antibody dilutions 
were used: 1:5000 for anti-CB1, and 1:10,000 for anti-tubulin. 
 
 
 
3.7. Morris water maze tests 
 
 The Morris water maze tests are used to investigate aspects of 
hippocampal-dependent spatial memory and how it is affected by 
pharmacological agents, lesions, gene mutations, age, or other 
pathological and physiological factors. In these tests, subjects 
(usually rats or mice) are essentially required to escape from water 
onto a hidden platform whose location is identified by using spatial 
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memory. The technique was developed by Richard Morris (Morris, 
1981; Morris et al., 1982) as a spatial localization or navigation task, 
and constitutes an alternate approach to studying spatial memory 
that addresses some of the problems of the radial arm maze task 
(reviewed by Olton, 1987; Brandeis et al., 1989). The differences 
between the radial arm maze and the water maze lie in the nature of 
the subject’s motivation to perform the task: food deprivation versus 
avoidance of drowning; and in the visibility of the location of the 
reward: a visible food cup versus a platform submerged in the water 
maze (Wenk, 1997). However, the main advantages of using the 
water maze over the radial arm maze are related to the animal’s 
innate ability to develop an optimal strategy to explore their 
environment and escape from the water in the quickest way possible. 
In support of the ecological relevance of the water maze task, it was 
observed that wild mice tested in the water maze out of doors can 
efficiently use celestial cues as spatial references (Kavaliers and 
Galea, 1994). 
 In the water maze, the navigation strategy thus relies heavily on 
using external visual cues as spatial references to locate the 
submerged escape platform (See Figure 3.7.1.). This also means 
that the animals have an allocentric representation of space, which 
allows the identification of whether an object or landmark has moved 
in relation to others. In contrast, an egocentric representation of 
space refers to the locations of objects relative to the viewer, thus 
directions need to change as the viewer moves. The allocentric 
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navigation utilizes the information stored as a “map” during previous 
processing (see Morris, 2007), and it is known that retrieving 
information from these “cognitive maps” requires the firing of 
hippocampal place cells (O'Keefe and Dostrovsky, 1971; O'Keefe 
and Nadel, 1978). The integrity of the hippocampus is therefore of 
utmost importance for spatial navigation. 
 
 
 
 
 Figure 3.7.1. Diagram illustrating the Morris water maze main 
apparatus. The animal’s navigation strategy relies heavily on using 
external visual cues as spatial references to locate the submerged escape 
platform. A video camera monitors the performance by tracking the 
subject’s movements and calculating distance travelled, latency to platform, 
and average speed. 
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3.7.1. Spatial reference memory task 
 
 The spatial reference memory (SRM) task is the basic and most 
common task used to test hippocampal memory with the Morris 
water maze (Morris, 1981; Morris et al., 1982). The reference 
memory protocol consists of placing the platform at one fixed water 
tank location, relative to the room’s visual cues, across 4 trials per 
animal per day, for 5 consecutive days. Mice were trained in this task 
before performing the short-term memory task (next section), in order 
to effectively learn the presence of an opportunity to escape and how 
to effectively use the external visual cues to reach it rapidly. 
 The apparatus consisted of a 1 m diameter swim tank of black 
infrared-translucent Perspex™, placed over an infrared light box 
(Tracksys, Nottingham, UK) in a room with various external cues 
visible from the pool. A 7 cm diameter transparent platform was ~0.5 
cm below the water surface. Water was allowed to equilibrate at 
room temperature (~23ºC) before tests were performed. An infrared 
sensitive camera positioned 2 m above the centre of the pool tracked 
all performances, using the Noldus Ethovision 7.0 software (Noldus 
Information Technology, The Netherlands). The latency, swim 
pathlength, and the average swim speed were the parameters 
measured.  
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 Animals randomly assigned to 4 experimental groups of 8 subjects 
(Table 3.7.1.) were habituated to experimental handling for 5 days 
prior to the beginning of experimentation (see figures 3.7.3. to 3.7.5.). 
 
 
Table 3.7.1. Experimental group assignment 
 
 
 
 
 Each symbol represents one subject in its cage. Two animals (symbol, 
underlined symbol) per cage were randomly assigned to one of four 
experimental groups (A-D).  
 
 The platform was placed into one quadrant of the pool, offset 
between subjects, but remaining in the same quadrant for each 
animal (Table 3.7.2., Figure 3.7.2.).  
 
 
Table 3.7.2.  Platform allocation in the spatial reference memory task. 
Mice Platform position 
,  N 
,  E 
,  S 
,  W 
 Each symbol and underlined symbol represents one half of the total 
animals in each cage. 
Group Cage 1 Cage 2 Cage 3 Cage 4 
A ,  ,  ,  ,  
B ,  ,  ,  ,  
C ,  ,  ,  ,  
D ,  ,  ,  ,  
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 Each subject was placed in the tank, facing the wall. To ensure 
that subjects used an allocentric navigation strategy, the quadrant in 
which animals were placed varied between trials each day, and 
different position sequences were used throughout days. To perform 
the task, mice were given 4 trials per day for 5 consecutive days. 
Each trial had a maximum duration of 60 seconds, and once the 
platform was reached animals were allowed a period of 20 seconds 
to acquire their position. If animals did not reach the platform after 60 
seconds, they were manually guided towards it. After each trial, mice 
were towel dried following removal from water, and placed in a 
waiting cage under a ceramic heating lamp until their next trial. The 
inter-trial interval was 15 minutes, to avoid hypothermia.  
 A probe test was performed 30 min after the last acquisition trial of 
the reference memory task, at the 5th day of training. The probe test 
consisted of one trial of 30 s where the animals were placed in the 
tank, after removal of the platform. The percentage of time spent in 
each quadrant was measured to assess the level of spatial memory. 
Based on the assessment that all subjects effectively spent a higher 
percentage of time in the training quadrant (results not shown), it was 
assumed that animals effectively learned to use an allocentric 
strategy, based on the external visual cues, to reach the goal. 
Therefore, subjects were subsequently tested in the trials to criterion 
protocol. 
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3.7.2. Trials to criterion (TTC) task  
 
 Other water maze tasks, such as the “reversal” test, the “delayed 
matching to place” (DMP), or the “trials to criterion” task (TTC) can 
be used to investigate different aspects of spatial memory, by testing 
specific hypotheses. They are mostly based on the same principles 
but apply different training and testing protocols that are often quite 
complex (Morris, 2007). 
 In the present thesis, the aim was to test the effects of chronic 
caffeine and THC on the subject’s ability to use short-term spatial 
memory, as it is known that short-term and working memory is 
particularly affected by cannabinoid CB1 receptor activation in the 
hippocampus (Varvel et al., 2001; da Silva and Takahashi, 2002; 
Varvel and Lichtman, 2002). These forms of memory, as evaluated in 
rodent models, have episodic-like characteristics, i.e. the memory of 
“what, when, where”, with respect to events (Morris, 2007). 
Furthermore, the hippocampal circuits associated with episodic-like 
memory are regulated by CB1 receptors (Robbe and Buzsáki, 2009). 
Therefore, a modified version of the Morris water maze task, the 
trials to criterion (TTC) task was applied. The TTC task is sensitive to 
hippocampal-dependent short-term, episodic-like spatial memory 
(Chen et al., 2000; Daumas et al., 2007; Daumas et al., 2008).  
 After being trained in the reference memory task to form a stable 
representation of the environment (see previous section), mice then 
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performed the TTC task, essentially according to the original protocol 
(Chen et al., 2000). Mice performed several tasks, each consisting of 
a new platform position (Table 3.7.3., Figure 3.7.2.).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.2. Diagram of the platform positions used in the Morris 
water maze. Left: schematic representation; Right: platform and quadrant 
zone definition set for tracking with the Ethovision software, overlaying a 
photograph taken by the camera positioned above the water tank.  
 
 Each animal was given a maximum of 8 trials per day, to perform 
the task until reaching a rigorous performance criterion of ≤ 7s 
average latency on three consecutive trials. When a subject did not 
reach criterion in 8 trials, testing in the same task recommenced the 
following day until criterion was reached. The optimal performance 
criterion of 7 seconds was selected based on observations from a 
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pilot experiment. It reflects the approximate minimum time taken by 
trained mice to reach the platform.  
 This strict criterion ensures that memory retrieval was selective for 
the most recently encoded location, and thus constitutes an 
“episodic-like” component of the task (Chen et al., 2000). The 
platform position varied between several possible locations, on two 
concentric circles, according to the original protocol (Table 3.7.3.).  
 
 
Table 3.7.3. Platform allocation in the trials to criterion task 
Task 
mice 1 2 3 4 5 6 7 8 
 iE oSW iN iS oNE iW oSE oNW 
 oSW iN oSE oNE iS oNW iE iW 
 iN oNW iE iW oSE iS oNE oSW 
 oNE iW oNW oSE iE oSW iN iS 
 oSW iE oNW oNE iW oSE iN iS 
 iN oSW iE iW oNE iS oNW oSE 
 oNW iS oNE oSE iN oSW iE iW 
 iS oNE iW iE oSW iN oSE oNW 
 
 Note that the platform position varied across tasks and between-subjects 
in order to avoid place preference and to evenly distribute each set of task 
conditions across all subjects. Each symbol and underlined symbol 
represents one half of the total animals in each cage. 
 
 
 Once the criterion was reached, trials stopped and a new task 
began on the following testing day. Animals first performed 4-5 
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training tasks in order to learn to optimize their search strategies, as 
indicated by asymptotic levels of performance across groups. The 
effects of acutely administered drugs, or vehicle were then tested in 
subsequent test tasks. At each test task, THC, WIN55,212-2 or 
vehicle, were acutely applied 30 min before first trial, whereas 
AM251 or DPCPX were applied 15 min before THC (or vehicle). 
There was a one-day rest period off-drug after each subject 
completed a test task to allow for the metabolization of THC. 
 The experimental design for each of the three behavioural 
experiments was as follows: 
  The first set of behavioural experiments was a dose-response 
study (Figure 3.7.3.) in which 1, 3 and 7 mg/kg THC (or vehicle) were 
tested at task 5. Task 6 was a control test in which no acute drug 
was given, to measure whether performance levels returned to 
baseline values. The same doses of THC (or vehicle) were then 
administered in the presence of CB1 receptor antagonist AM251 (3 
mg/kg) at task 7. 
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 Fig 3.7.3. Timetable and experimental design for the THC dose-
response study. (a) experimental time course; (b) treatment groups; (c) 
experimental design. Note that half of the subjects in each group (I) were 
tested in a first stage, and the second half (II) in a second stage, to 
accommodate the maximum practicable number of trials per day.  
 The second set of experiments (Figure 3.7.4.) was performed on 
chronic caffeine (or vehicle) treated mice, to which 5 mg/kg THC (or 
vehicle) was acutely administered at task 6, and the effect of THC (or 
vehicle) was tested in the presence of 3 mg/kg AM251 at task 7.  
(one day rest off-drug between test tasks  
– Task 6 was performed as a control in absence of THC) 
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 Fig 3.7.4. Timetable and experimental design for the second set of 
behavioural experiments. (a) experimental time course; (b) treatment 
groups; (c) experimental design. Note that, for the chronic caffeine 
treatment and trials to criterion task, half of the subjects in each group (I) 
were tested in a first stage, and the second half (II) in a second stage, to 
accommodate the maximum practicable number of trials per day. AM251 
was given 15 min before THC, which was given 30 min before testing. 
(one day rest off-drug 
between test tasks) 
daily (>15 days 
before 1st THC inj.) 
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 The third set of experiments (Figure 3.7.5.) was also performed on 
chronic caffeine (or vehicle) treated mice. The effects 5 mg/kg THC 
(or vehicle) were tested at task 5. Task 6 was a control test in which 
no acute drug was given, and, the effects of THC (or vehicle) in the 
presence of A1 receptor antagonist DPCPX (1 mg/kg) were tested at 
task 7. Lastly, the effect of 1 mg/kg WIN55,212-2 (or vehicle) was 
tested at task 8.  
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  
 Fig 3.7.5. Timetable and experimental design for the third set of 
behavioural experiments. (a) experimental time course; (b) treatment 
groups; (c) experimental design. Note that, for the chronic caffeine 
treatment and trials to criterion task, half of the subjects in each group (I) 
were tested in a first stage, and the second half (II) in a second stage, to 
accommodate the maximum practicable number of trials per day. DPCPX, 
was given 15 min before THC, which was given 30 min before testing. 
WIN55,212-2 (WIN) was administered 30 min before testing. 
 
3.8. Statistics 
 
 Statistical significance was tested using paired Student’s t-test, 
one-way or two-way analysis of variance (ANOVA), followed by 
Dunnett’s or Tukey’s post hoc tests, as indicated. The two-way 
ANOVA and post hoc tests were performed using the Predictive 
Analytics Software 18.0 (SPSS Inc., an IBM Company, Chicago, IL).  
 GraphPad Prism 5.0 (GraphPad Prism Software Inc., San Diego, 
CA) was used for all other statistical tests and for nonlinear 
regression curve fitting of specific binding curves. The statistical 
significance of the differences in the binding curve parameters (Bmax 
and KD; or EC50, and Emax), between treatments, was tested using 
the extra sum-of-squares F test. 
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 All values obtained represent the mean ± standard error of the 
mean (s.e.m.) of the indicated number of experiments. Statistical 
differences were considered significant at a p-value of ≤ 0.05. 
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4. Results and discussion 	  
4.1. Modulation of cannabinoid CB1 signalling by 
adenosine A1 receptors in the rat hippocampus 
 
 The A1 and CB1 receptors are heavily expressed in the brain, 
with particular predominance and co-expression in the hippocampus, 
cortex and cerebellum (Herkenham et al., 1990; Ribeiro et al., 2002). 
Both receptors regulate synaptic transmission through activation of 
G-protein αi/o subunits (Straiker et al., 2002) and similar second 
messenger systems (Dunwiddie and Masino, 2001; Howlett, 2005).  
 In the cerebellum, there is evidence that A1 receptors modulate 
the motor incoordination effects induced by acute administration of 
CB1 receptor agonists (Dar, 2000; DeSanty and Dar, 2001; Dar and 
Mustafa, 2002). There is also evidence that prolonged administration 
of a CB1 or A1 agonist induces cross-tolerance in the cerebellum and 
hippocampus (DeSanty and Dar, 2001; Kouznetsova et al., 2002; 
Selley et al., 2004). More recently, a study observed that CB1-
mediated inhibition of excitatory synaptic transmission in the 
hippocampus is modulated by endogenous adenosine, through A1 
receptor activation (Hoffman et al., 2010).  
 These previous findings raised the hypothesis that CB1 receptor 
signalling in the hippocampus is under the modulatory control of A1 
receptors. Therefore, given the predominant distribution of CB1 
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receptors in GABAergic neurons of the hippocampus, the present 
work initially focused on the influence of a putative A1-CB1 receptor 
interaction upon the release of GABA from hippocampal 
synaptosomes. This hypothesis was tested by first measuring the 
influence of A1 receptor activation on the CB1-dependent inhibition of 
K+-evoked [3H]GABA release from rat hippocampal synaptosomes. 
Furthermore, the influence of A1 receptor activation on the CB1-
dependent inhibition of K+-evoked [3H]glutamate release was also 
tested. Finally, [35S]-GTPγS binding assays were performed to test 
whether the interaction occurred at the level of G-protein activation. 
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4.1.1. Calcium dependence of the K+-evoked [3H]GABA release 
from rat hippocampal synaptosomes 	  
 In control conditions, pooling data from all experiments performed, 
the average basal release of [3H]GABA from rat hippocampal 
synaptosomes was 0.76±0.02% of the total tritium retained by 
synaptosomes per experiment (n=31, average of first 6 min of 
collection, data not shown). Depolarization of the hippocampal 
synaptosomes with K+ (15 mM) for 2 min induced a 3-fold increase in 
the [3H]GABA release with an average peak of 2.5±0.1% during S1, 
and 2.3±0.1% during S2, giving an average S2/S1 of 0.94±0.01 (n=31, 
data not shown). As Figure 4.1.1. shows, the depolarization by K+ 
mainly induced a calcium-dependent release of [3H]GABA, since 
blockade of voltage-gated Ca2+ channels (VGCCs) by Cd2+ (CdCl2, 
200 µM) inhibited its release by 70±3% (n=8, p<0.001, Figure 
4.1.1.b). The GABA transporters account for the remaining 
percentage of [3H]GABA released, since blockade of GABA 
transporters with SKF89976a (SKF, 20 µM) prevented [3H]GABA 
release by 34±2% (n=8, p<0.001, Figure 4.1.1.b). The co-application 
of SKF and CdCl2 blocked 86±2% of the total [3H]GABA release 
(n=2, p<0.001, Figure 4.1.1.b), however the residual [3H]GABA 
release in these conditions may be dependent on the Ca2+ released 
from internal Ca2+ stores of the synaptosomes. 
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 Since exocytotic neurotransmitter release is a functionally relevant 
phenomenon to synaptic transmission, and it is significantly 
dependent on the influx of Ca2+ through VGCCs, the K+-evoked 
[3H]GABA release, measured in the present thesis, is therefore 
considered functionally relevant. 
 
Figure 4.1.1. Calcium dependence of the K+ -evoked [3H]GABA release 
from rat hippocampal synaptosomes. (a) Fractional release of [3H]GABA  
evoked by one 15 mM K+ stimuli of 2 min duration (as indicated by the 
horizontal bar) in the absence (control, n=16) and in the presence of VGCC 
blocker Cd2+ (CdCl2, 200 µM, n=8), GABA transporter inhibitor SKF89976a 
(SKF, 20 µM, n=8), or both (SKF+CdCl2, n=2). (b) Effect of SKF, CdCl2 and 
SKF+CdCl2 on [3H]GABA release, represented as percentage of control. 
CdCl2, SKF, or both together, were applied 15 minutes before sample 
collection and continuously perfused until the end of the experiment. Data 
represent mean ± s.e.m. from the indicated number of experiments, 
performed in duplicate. Non-visible error bars are within symbols. 
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4.1.2. Characterization of the CB1 receptor-dependent inhibition 
of K+-evoked [3H]GABA release from rat hippocampal 
synaptosomes 
 
 
 The potent cannabinoid receptor agonist WIN55,212-2 was used 
to induce a CB1 receptor-dependent effect on [3H]GABA release. 
Since WIN55,212-2 is known to directly block N-type VGCCs at 
concentrations above 1 µM (Shen and Thayer, 1998; Németh et al., 
2008), we tested the specificity of its effect in our preparation using 
the CB1 antagonist AM251, as well as WIN55,212-3, an enantiomer 
of WIN55,212-2 that does not activate the CB1 receptor but maintains 
the Ca2+ channel blocking properties at high micromolar 
concentrations (Shen and Thayer, 1998).  
 The effect of WIN55,212-2 (0.01-10 µM) on K+-evoked [3H]GABA 
release was concentration-dependent (Figure 4.1.2.e). Since 
WIN55,212-2 is known to directly block N-type VGCCs at 
concentrations above 1 µM (Shen and Thayer, 1998; Németh et al., 
2008), the specificity of its effect was tested in this preparation using 
the CB1 antagonist AM251, as well as WIN55,212-3, an enantiomer 
of WIN55,212-2 that does not activate the CB1 receptor but maintains 
the Ca2+ channel blocking properties (Shen and Thayer, 1998). 
AM251 (1 µM) fully blocked the effect of 1 µM but not of 10 µM of 
WIN55,212-2 (Figure 4.1.2.a-e). Higher concentrations of AM251 
were not used to avoid loss of selectivity (see Köfalvi et al., 2007; 
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Köfalvi, 2008). The enantiomer had no significant effect applied at 1 
µM but it inhibited evoked [3H]GABA release by 22.4±1.4% at 10 µM 
(n=5, p<0.05. Figure 4.1.2.e), which indicates that the effect of 1 µM 
WIN55,212-2 upon [3H]GABA release is CB1 receptor-dependent. It 
is noteworthy that the effect of 10 µM WIN55,212-2 was larger than 
the effect of 10 µM WIN55,212-3, which indicates that the effect of 10 
µM WIN55,212-2 still encompasses a CB1 receptor-dependent 
component. The partial CB1 agonist Δ9-Tetrahydrocannabinol (THC, 
1 µM) inhibited K+-evoked [3H]GABA release by 8.9±0.9% (n=8, 
p<0.05, Figure 4.1.2.e). 
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 Figure 4.1.2. Concentration-dependent and CB1 receptor-selective 
effects of WIN55,212-2 (WIN) on the K+-evoked release of [3H]GABA. 
(a-d) Average fractional release of [3H]GABA, from two sets of 
experiments. (a,b) shows the effect of 1 µM WIN in the absence (a), and in 
the presence (b) of the CB1 receptor antagonist, AM251 (1 µM). (c,d) 
shows the effect of 10 µM WIN in the absence (c), and in the presence (d) 
of AM251. Synaptosomes were incubated with [3H]GABA, and 
neurotransmitter release was evoked by two 15 mM K+ stimuli of 2 min 
duration, as indicated (S1 and S2). All points in (a,b) and (c,d) represent the 
mean ± s.e.m. of 3 experiments performed in duplicate, each of which 
using the same batch of synaptosomes. (e) Concentration-dependent 
inhibition of K+-evoked release of [3H]GABA, induced by WIN (0.01–10 µM); 
the effect of partial CB1 receptor agonist, THC (1 µM), as well as of a WIN 
enantiomer that is inactive at the CB1 receptor, WIN55,212-3 (WIN-3; 1-10 
µM), is also shown. WIN significantly inhibited [3H]GABA release at all 
concentrations (p<0.01), except for the lowest concentration tested (0.01 
µM, p>0.05); THC (1 µM) also significantly inhibited [3H]GABA release 
(p<0.01). Note that WIN-3 was devoid of effect at 1 µM (p>0.05), but not at 
10 µM (p<0.01), and that AM251 antagonized the effect of 1 µM but not of 
10 µM WIN (also shown in a-d), indicating that WIN is CB1 receptor-
selective at 1 µM, but not at 10 µM. All data points represent the 
mean±s.e.m. of 4 to 10 independent experiments performed in duplicate, 
except (n=2) for 0.01 µM and 3 µM WIN, and 1 µM WIN-3. The S2/S1 
values from corresponding controls were taken as 0% within each 
experiment. P-values were obtained by a one-way ANOVA test with 
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Dunnett post hoc, compared to control (0%). AM251 was applied 15 min 
before start of sample collection and was continuously perfused throughout 
the experiment, being therefore present during S1 and S2 (indicated by the 
horizontal bars); WIN, WIN-3 and THC were added before S2 (see section 
3.4.1. for further details). 
 
 The effects of 1 µM WIN55,212-2 upon the [3H]GABA released by 
GABA transporters, and by exocytosis, were then evaluated.  
 The blockade of GABA transporters with SKF89976a (20 µM) did 
not alter the effect of WIN55,212-2 (p>0.05, n=5, Figure 4.1.3.a,b,e) 
To evaluate whether 1 µM WIN55,212-2 inhibited the Ca2+-
dependent exocytotic release of [3H]GABA, the influence of VGCCs 
blocker Cd2+ (CdCl2, 200 µM) was tested. Application of CdCl2 
completely abolished the effect of WIN55,212-2 at its maximum CB1-
specific concentration (n=5, p<0.01, Figure 4.1.3.c,d,e), which 
suggests that the effect of 1 µM WIN55,212-2 upon [3H]GABA 
release is exerted through the inhibition of Ca2+-dependent exocytotic 
release.  
 Pooling data from all experiments performed, the application of 
this selective concentration of WIN55,212-2 six minutes before S2, 
caused a decrease of basal [3H]GABA outflow and inhibited evoked 
GABA release with an average S2/S1 of 0.78±0.01 that represents an 
inhibition of 16.7±1.4% (n=31, data not shown), when compared to 
control S2/S1 within each experiment. This effect is comparable to 
A1-­‐CB1	  receptor	  interplay	  in	  the	  hippocampus	  
	  78	  
that reported in a previous study using a similar method (Köfalvi et 
al., 2007). 
 
 
 
Results	  and	  discussion	  
	   79	  
 
  
Figure 4.1.3. Effect of WIN55,212-2 is exerted through the inhibition of 
Ca2+-dependent exocytotic [3H]GABA release. Average fractional 
release of [3H]GABA from two sets of experiments. (a-d) shows the effect 
of 1 µM WIN55,212-2 (WIN) in the absence (a), or in the presence (b) of 
the GABA transporter blocker, SKF89976A (SKF, 20 µM). (c,d) shows the 
effect of 1µM WIN in the absence (c), or in the presence (d) of the VGCC 
blocker Cd2+ (CdCl2, 200 µM). Synaptosomes were incubated with 
[3H]GABA, and neurotransmitter release was evoked by two 15 mM K+ 
stimuli of 2 min duration, as indicated (S1 and S2). All points in (a,b) and 
(c,d) represent the mean ± s.e.m.  of 5 experiments performed in duplicate, 
each of which using the same batch of synaptosomes. (e) Histogram 
representing the effects from the experiments shown in (a-d) as percentage 
inhibition of [3H]GABA release induced by WIN in the absence or in the 
presence of CdCl2, or SKF (as indicated below each bar), Note that CdCl2, 
but not SKF, fully blocked the effect of WIN (n=5, **p<0.01, paired 
Student’s t-test vs. effect of WIN alone within the same batch of 
synaptosomes). The S2/S1 values from corresponding controls were taken 
as 0% within each experiment. SKF and CdCl2 were applied 15 min before 
start of sample collection and was continuously perfused throughout the 
experiment, being therefore present during S1 and S2, WIN, was added 
before S2 (indicated by the horizontal bars, see section 3.4.1. for further 
details). 
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4.1.3. A1 receptors attenuate the CB1 receptor-dependent 
inhibition of K+-evoked [3H]GABA release from rat hippocampal 
synaptosomes 	  
 Consistent with previous observations (Cunha and Ribeiro, 2000), 
adenosine A1 receptor activation with the selective agonist CPA (100 
nM), applied before S2, did not affect K+-evoked [3H]GABA release 
(2.7±3% inhibition of control S2/S1, n=3, p>0.05, data not shown). 
Nevertheless, A1 receptors are present in GABAergic neurons of the 
hippocampus (Ochiishi et al., 1999) where they appear to maintain a 
cross-modulatory role (Cunha-Reis et al., 2008). Therefore, to 
evaluate the influence of A1 receptors on the CB1-mediated inhibition 
of GABA release, the effect of WIN55,212-2 was tested in the 
absence and in the presence of presence of CPA (100 nM). Under 
these conditions, the effect of WIN55,212-2 at 1 µM (n=10, Figures 
4.1.4a and 4.1.6a) and at 10 µM (n=7, Figures 4.1.4c and 4.1.6a) 
was significantly attenuated (p<0.01 and p<0.05, respectively). The 
average effect of 1 µM WIN55,212-2 was 18±3% (n=10) and CPA 
attenuated this effect to 12±2% (p<0.01, n=10), which represents a 
33±13% decrease in the average effect of WIN55,212-2 alone. 
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 Figure 4.1.4. Effect of WIN55,212-2 (WIN) on [3H]GABA release is 
attenuated by CPA. Average fractional release of [3H]GABA, from three 
sets of experiments. (a,b) shows the effect of 1 µM WIN in the absence (a), 
or in the presence (b) of the A1 receptor agonist CPA (100 nM). (c,d) 
shows the effect of 10 µM WIN in the absence (c), or in the presence (d) of 
CPA. (e,f) shows the effect of CB1 receptor-inactive enantiomer, 
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WIN55,212-3 (WIN, 3, 10 µM), in absence (e), or in the presence (f) of CPA 
.Synaptosomes were incubated with [3H]GABA, and neurotransmitter 
release was evoked by two 15 mM K+ stimuli of 2 min duration, as indicated 
(S1 and S2). All points in (a,b), (c,d) and (e,f) represent the mean ± s.e.m. 
of n=7-10 (a-d) or n=3 (e,f) performed in duplicate, each of which using the 
same batch of synaptosomes. CPA was applied 15 min before start of 
sample collection and was continuously perfused throughout the 
experiment, being therefore present during S1 and S2 (indicated by the 
horizontal bars); WIN or WIN-3 were added before S2 (see section 3.4.1. 
for further details). For better comparison of the effects, these results are 
shown as percentage inhibition in Figure 4.1.6. 
 
 
 Since A1 receptor activation also affects VGCCs (Ambrósio et al., 
1997), the attenuation of the effect of 10 µM WIN55,212-2 by CPA 
could indicate that it occurred through a Ca2+ channel-dependent 
mechanism, and not involving CB1 receptors since, at high 
micromolar concentrations, WIN55,212-2 blocks N-type VGCCs 
(Shen and Thayer, 1998; Németh et al., 2008).  To test if CPA 
attenuated the CB1 receptor-dependent effects of WIN55,212-2, 
experiments were performed using the enantiomer WIN55,212-3. 
Application of WIN55,212-3 (10 µM) by itself inhibited [3H]GABA 
release by 22±2%, while in presence of CPA (100 nM) its effect was 
unaltered (22±2%, p>0.05, n=3, Figures 4.1.4e,f and 4.1.6a), 
indicating that the effect of CPA did not involve Ca2+channel-
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dependent mechanisms affected by high concentrations of 
WIN55,212-2.  
 
Figure 4.1.5. CPA-induced attenuation of the effect of WIN55,212-2 
(WIN) on [3H]GABA release is A1 receptor-specific. Average fractional 
release of [3H]GABA, from three sets of experiments. (a,b) shows the effect 
of 1 µM WIN in the absence (a), or in the presence (b) of the A1 receptor 
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antagonist DPCPX (50 nM) alone, and in combination with CPA. (c,d) 
shows the effect of 10 µM WIN in the absence (a), or in the presence (b) of 
DPCPX alone, and in combination with CPA. (e,f) shows the effect of 1 µM 
WIN, in absence (e), or in the presence (f) of the selective GABAB receptor 
agonist, baclofen (10 µM). Synaptosomes were incubated with [3H]GABA, 
and neurotransmitter release was evoked by two 15 mM K+ stimuli of 2 min 
duration, as indicated (S1 and S2). All points in (a,b), (c,d) and (e,f) 
represent the mean ± s.e.m. of n=7 (a-d) or n=5 (e,f), performed in 
duplicate, each of which using the same batch of synaptosomes, except 
‘DPCPX’ alone (S1+S2) (b,d), which was included in the graphs to illustrate 
absence of effect on S2/S1. CPA was applied 15 min before start of sample 
collection and was continuously perfused throughout the experiment, being 
therefore present during S1 and S2 (indicated by the horizontal bars); WIN 
was added before S2, whereas the other drugs were applied 15 min (CPA 
or baclofen) or 30 min (DPCPX) before the start of sample collection, being 
therefore present during S1 and S2 (see section 3.4.1. for further details). 
For better comparison of the effects, these results are shown as 
percentage inhibition in Figure 4.1.6. 
 
 
 To test if the CPA-induced attenuation of the effect of WIN55,212-
2 was A1 receptor specific, the A1 receptor antagonist DPCPX was 
used. The blockade of A1 receptors with DPCPX (50 nM) did not, on 
its own, alter the effects of 1 µM and 10 µM WIN55,212-2, but it fully 
prevented the CPA-induced attenuation (p>0.05, n=7, Figures 
4.1.5a-d and 4.1.6b).  
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  
Figure 4.1.6. A1 receptor activation significantly attenuates the CB1-
mediated inhibition of [3H]GABA. Percentage inhibition of the effects 
observed on experiments shown in Figures 4.1.4 and 4.1.5. (a) Effects of 
WIN55,212-2 (WIN, 1 and 10 µM) and WIN55,212-3 (WIN-3, 10 µM), in 
absence or in the presence of CPA (100 nM), as indicated below each 
column. Note that CPA significantly attenuated the effect of 1 and 10 µM 
WIN (**p<0.01; *p<0.05), while the effect of WIN-3 (10 µM) was unaffected 
by CPA (p>0.05). (b) WIN (1 and 10 µM) was tested in the absence or in 
the presence of DPCPX (50 nM), alone and in combination with CPA. (c) 
WIN (1 µM) was tested in the absence or in the presence of baclofen (10 
µM), as indicated below the column. Note that in the presence of DPCPX, 
CPA did not attenuate the inhibitory effect of WIN (p>0.05), and that 
baclofen did not modify the effect of WIN (1 µM) (p>0.05). Bars represent 
the mean ± s.e.m. of 3–10 individual experiments performed in duplicate. 
The S2/S1 values from controls were taken as 0% within each experiment. 
P-values were obtained by paired Student’s t-test, compared to 
corresponding controls within the same batch of synaptosomes. 
 
 
 
 The signalling pathways of CB1, A1 and GABAB are known to 
converge when co-expressed in cerebellar neurons (Selley et al., 
2004). Furthermore, both CB1 and GABAB receptors are present in 
inhibitory interneurons (Katona et al., 1999; Sloviter et al., 1999), 
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couple to the same Gαi/o subunits (Straiker et al., 2002) and exhibit 
reciprocal inhibition (Cinar et al., 2008) in hippocampal neurons. To 
evaluated whether the A1 receptor-dependent attenuation of the 
effect of WIN55,212-2 was mimicked by activation of GABAB 
receptors, the effect of 1 µM WIN55,212-2 was tested in the 
presence of GABAB specific agonist baclofen. As shown in Figures 
4.1.5e,f and 4.1.6c, the effect of WIN55,212-2 (1 µM) was 
unchanged (p>0.05, n=5) in the presence of baclofen (10 µM). 
Altogether, these results indicate that the cannabinoid CB1 receptors 
in GABAergic nerve terminals are under the modulatory influence of 
adenosine A1 receptors, but not GABAB receptors. 
 
 Lastly, the effect of CB1 receptor partial agonist THC was tested in 
the absence or in the presence of CPA. A saturating and CB1 
receptor-selective concentration of THC (1 µM) was selected based 
on previous findings (Breivogel et al., 1998). As shown in Figure 
4.1.7, THC (1 µM) by itself inhibited [3H]GABA release by 9±1%, 
while in the presence of CPA (100 nM), the inhibition was slightly 
smaller (6±2%), though it did not reach statistical significance 
(p>0.05, n=7) possibly due to the small magnitude of effect in the 
absence of CPA. 
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Figure 4.1.7. Inhibition of [3H]GABA release by partial CB1 receptor 
agonist THC is marginally attenuated by CPA. (a,b) Average fractional 
release of [3H]GABA from one set of experiments, showing  the effect of 1 
µM THC in the absence (a), or in the presence (b) of CPA (100 nM). (c) 
Histogram representing the effects as percentage inhibition of [3H]GABA 
release. Note that CPA had no significant effect on the low percentage of 
inhibition induced by 1 µM THC (p>0.05). All data represent the mean ± 
s.e.m. of 7 experiments performed in duplicate. The S2/S1 values from 
corresponding controls were taken as 0% within each experiment (see 
section 3.4.1. for further details). P-value was obtained by paired Student’s 
t-test, compared to the effect of THC in absence of CPA within the same 
batch of synaptosomes. 
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4.1.4. A1 receptors attenuate the CB1 receptor-dependent 
inhibition of [3H]glutamate release from rat hippocampal nerve 
terminals 
 
 Despite the predominant influence of CB1 receptors in 
hippocampal circuitry being exerted through the inhibition of GABA 
release, CB1 receptors at glutamatergic presynaptic nerve terminals 
(Katona et al., 2006; Kawamura et al., 2006) also inhibit the K+-
evoked release of glutamate (e.g. D'Amico et al., 2004; Cannizzaro 
et al., 2006; Köfalvi et al., 2007). Importantly, the regulation of 
excitatory synaptic transmission is the most relevant role of the 
hippocampal A1 receptors (Dunwiddie and Fredholm, 1989; 
Sebastião et al., 1990). To investigate whether A1 receptors also 
regulate the CB1-dependent effects on glutamate release, the 
influence of A1 receptor activation on the CB1-dependent inhibition of 
K+-evoked [3H]glutamate release was also tested. 
 The absence of a tonic activation of A1 receptors by endogenous 
adenosine was first assessed by using A1 receptor blocker DPCPX. 
As Figures 4.1.8a,b and 4.1.9a show, WIN55,212-2 (1 µM) inhibited 
the release of [3H]glutamate by 16±2%. The blockade of A1 receptors 
with DPCPX (50 nM) did not modify the effect of WIN55,212-2 
(15±1%p>0.05, n=4), which indicates that endogenous adenosine 
was effectively washed out by the continuous vertical flow of 
superfusion medium (see section 3.4.1.).  
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Figure 4.1.8. A1 receptor activation attenuates the CB1-dependent 
effects upon [3H]glutamate release. Average fractional release of 
[3H]GABA, from three sets of experiments. (a,b) shows the effect of 1 µM 
WIN in the absence (a), or in the presence (b) of DPCPX (50 nM). (c,d) 
shows the effect of 1 µM WIN in the absence (c), or in the presence (d) of 
CPA (100 nM). (e,f) shows the effect of 100 nM CPA, in absence (e), or in 
the presence (f) of WIN (1 µM). Synaptosomes were incubated with 
[3H]GABA, and neurotransmitter release was evoked by two 15 mM K+ 
stimuli of 2 min duration, as indicated (S1 and S2). All points in (a,b), (c,d) 
and (e,f) represent the mean ± s.e.m. of 5 experiments performed in 
duplicate, each of which using the same batch of synaptosomes (see 
section 3.4.1. for further details). For better comparison of the effects, these 
results are shown as percentage inhibition in Figure 4.1.9. 
 
 
 The inhibition of [3H]glutamate release induced by 1 µM 
WIN55,212-2 (19±2%, n=5), was significantly attenuated in the 
presence of CPA (7±2%, n=5, p<0.01, Figures 4.1.8c,d and  4.1.9b). 
This further indicates that A1 receptors negatively modulate the CB1-
mediated effects in the hippocampus. 
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Figure 4.1.9. A1 receptors modulate the CB1-mediated inhibition of 
[3H]glutamate. Percentage inhibition of the effects observed on 
experiments shown in Figure 4.1.8 (a) Blockade of A1 receptors by DPCPX 
(50 nM) did not modify (p>0.05) the effect of WIN55,212-2 (WIN, 1 µM). (b) 
The inhibition induced by WIN (1 µM) was significantly (**p<0.01) 
attenuated by CPA (100 nM, present throughout S1 and S2), but the effect 
of CPA alone (applied only before S2) was not modified (p>0.05) when 
applied in presence of WIN (1 µM, presend throughout S1 and S2). Bars 
represent the mean ± s.e.m. of 5 individual experiments performed in 
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duplicate. The S2/S1 values from controls were taken as 0% within each 
experiment. P-values were obtained by paired Student’s t-test, compared to 
corresponding controls within the same batch of synaptosomes. 
 
 
 To investigate whether the A1-mediated effects on glutamate 
release are also under the modulatory control of CB1 receptors, we 
tested the effects of CPA (applied before S2) in the presence of 
WIN55,212-2. CPA (100 nM) inhibited [3H]glutamate release by 
12±4% (n=4), and this effect was not modified in the presence of 1 
µM WIN55,212-2 (13±2%, n=4, p>0.05, Figures 4.1.8e,f and 4.1.9b). 
These findings suggest that the A1 is the dominant receptor, 
negatively modulating CB1-mediated effects. 
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4.1.5. Effect of A1-CB1 receptor interaction on the stimulation of 
G-proteins in hippocampal membranes 
 
 To test whether the adenosine-cannabinoid interaction occurs at 
the level of G-protein activation, we measured agonist-stimulated 
[35S]-GTPγS binding in hippocampal membranes with the full agonist 
of CB1 receptors, WIN55,212-2, or with the partial agonist THC, in 
absence and in the presence of A1 receptor agonist CPA.  
 The basal [35S]GTPγS binding in the absence of WIN55,212-2 
(Figure 4.1.10a.) or THC (Figure 4.1.10b.) is represented as 100% in 
the ordinates, which corresponds to (fmol/mg protein): Figure 3a: 149 
± 16 in control (, n=7), 311 ± 50 in presence of CPA (, n=4), and 
331 ± 74 in presence of baclofen (, n=4); Figure 3b: 98 ± 4 in 
control (, n=4), 255 ± 25 in presence of CPA (, n=4), and 161 ± 
15 in presence of baclofen (, n=4). 
 When applied alone, WIN55,212-2 (0.1 nM-10 µM) concentration-
dependently stimulated [35S]-GTPγS binding, with an EC50 ≈255 nM 
and Emax=251±7% (Figure 4.1.10a., Table 4.1.1., n=7). CPA (100 
nM) by itself induced a 150±12% net increase from basal [35S]-
GTPγS binding (n=4). 
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Table 4.1.1. Emax and log EC50 values of agonist-stimulated [35S]GTPγS 
binding in rat hippocampal membranes. 
 
 
 
 
 
 
 
 
 
 
 Note that the A1 receptor agonist CPA (100 nM) significantly decreased 
the Emax of WIN55,212-2 (WIN) and THC-stimulated [35S]GTPγS binding, 
but not the EC50; The GABAB receptor agonist baclofen (100 µM) had no 
significant influence. Data represent mean values ± s.e.m (n=4) obtained 
from nonlinear regression analyses of the data shown in Figure 4.1.10. 
*p<0.05, compared to appropriate control, calculated using the extra sum-
of-squares F test. 
 
 Co-application of WIN55,212-2 (0.1 nM-10 µM) with 100 nM CPA 
(Figure 4.1.10a.) significantly decreased the Emax of WIN55,212-2 to 
204±10% (Table 4.1.1., p<0.001, n=4), but not the EC50 (≈177 nM). 
Similarly, the co-application of THC (0.1 nM-1 µM) with 100 nM CPA 
(Figure 4.1.10b.) significantly decreased the Emax of THC from 
163±8% (when applied alone) to 129±13% (Table 4.1.1., n=4, 
p<0.05), but not the EC50. This indicates a functional interaction 
 EC50 Emax 
 -log,  M % of stimulation 
WIN -6.589 ± 0.11          251 ± 7 
WIN + CPA -6.752 ± 0.23   204 ± 10 * 
WIN + baclofen -6.554 ± 0.20 257 ± 12 
THC -6.837 ± 0.20          163 ± 8 
THC + CPA -6.870 ± 0.72   129 ± 13 * 
THC + baclofen -6.765 ± 0.26          157 ± 9 
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between co-localized CB1 and A1 receptors in hippocampal 
membranes, which impacts on the ability of CB1 receptors to activate 
Gαi/o-proteins.  
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Figure 4.1.10. Influence of A1 or GABAB receptor activation on CB1-
induced stimulation of G-proteins, as assayed by WIN55,212-2 or THC-
induced [35S]GTPγS binding. Rat hippocampal membranes (10 µg 
protein) were incubated for 30 min at 37o C with 30 µM GDP, 0.1 nM 
[35S]GTPγS and varying concentrations of (a) WIN55,212-2 (0.1 nM – 10 
µM) or (b) THC (0.1 nM – 1 µM), alone () or in combination with 100 nM 
CPA (), or 100 µM baclofen (). Emax and log EC50 values are shown in 
Table 1. Data represent mean percentage of basal stimulation ± s.e.m. of 
n=7 () and n=4 (, ), performed in duplicate. Non-visible error bars are 
within symbols. 
 
 To examine if other Gαi/o coupled receptors are also capable of 
interfering with the G-protein coupling of CB1 receptors, we tested 
whether combined activation of CB1 and GABAB receptors in the 
hippocampus would also affect the efficacy of WIN55,212-2 in [35S]-
GTPγS binding. To activate GABAB receptors we used 100 µM 
baclofen, which by itself induced a 118±11% net increase from basal 
[35S]-GTPγS binding (n=4), that was not significantly different from 
the effect of 100 nM CPA. As shown in Figure 4.1.10a,b and Table 
4.1.1., 100 µM baclofen did not affect the WIN55,212-2-induced 
(Emax=257±12%, n=4) or THC-induced (Emax=157±9%, n=4) 
stimulation of [35S]-GTPγS binding. The reduced efficacy in 
stimulation of [35S]-GTPγS binding by CB1 with A1 but not GABAB 
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suggests that the adenosine A1 receptors play a specific role in 
modulating CB1 signalling in hippocampal presynaptic terminals 
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4.1.5. Discussion 
 
 The findings reported in this chapter demonstrate that adenosine 
A1 receptors exert a negative modulatory effect on the cannabinoid 
CB1-mediated inhibition of GABA and glutamate release from rat 
hippocampal synaptosomes. It was further observed that this 
interaction occurs at the level of G-protein activation. 
 
 The CB1 receptor-mediated modulation of GABA release from 
hippocampal CCK-positive interneurons is a critical mechanism for 
spatial and episodic memory, as these interneurons regulate the 
temporal coordination of principal cell assemblies (Hájos et al., 2000; 
Robbe et al., 2006; Robbe and Buzsáki, 2009). Moreover, the CB1 
receptors localized at GABAergic, but not glutamatergic, neurons 
mediate the amnesic effects of THC (Puighermanal et al., 2009). The 
potent CB1 receptor agonist WIN55,212-2 inhibited calcium-
dependent [3H]GABA release with a maximum CB1-specific effect at 
1 µM, in agreement with studies in human post-mortem and rodent 
tissue, where the effects of CB1 agonists on the release of [3H]GABA 
from hippocampal synaptosomes were first characterized (Katona et 
al., 2000; D'Amico et al., 2004; Köfalvi et al., 2007).  
 On the other hand, the A1 receptors expressed in GABAergic 
interneurons of the adult rodent hippocampus (Ochiishi et al., 1999) 
do not directly influence GABA release (Cunha and Ribeiro, 2000), 
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but operate as modulators of other neuromodulators, as reported for 
vasoactive intestinal peptide (VIP) signalling (Cunha-Reis et al., 
2008). In the present work, it was found that the inhibition of 
[3H]GABA release from rat hippocampal synaptosomes caused by 
WIN55,212-2 was significantly attenuated by the selective A1 
receptor agonist CPA, and this attenuation was prevented by 
previous blockade of A1 receptors with DPCPX. However, CPA could 
not significantly attenuate the low percentage of inhibition of 
[3H]GABA release exerted by THC, which was used at a maximal 
concentration (Breivogel et al., 1998). THC behaves as a partial 
agonist at the CB1 receptor, it has a lower affinity and relative 
intrinsic activity than WIN55,212-2 and other commonly used CB1 
agonists (Pertwee, 2005). Therefore, the lack of attenuation of the 
effect of THC on [3H]GABA release by CPA might be explained by 
the small magnitude of the effect, which possibly represented a 
below-threshold population of the CB1 receptors that are co-localized 
with A1 receptors. 
 CB1 receptors at hippocampal glutamatergic presynaptic nerve 
terminals also inhibit the release of glutamate (e.g. D'Amico et al., 
2004; Cannizzaro et al., 2006; Köfalvi et al., 2007), which is, 
conversely, the most relevant property of hippocampal A1 receptors, 
which leads to the inhibition of excitatory synaptic transmission 
(Dunwiddie and Fredholm, 1989; Sebastião et al., 1990). 
Accordingly, both WIN55,212-2 and CPA significantly inhibited 
[3H]glutamate release. However, there was no tonic activation of A1 
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receptors by endogenous adenosine in these experimental 
conditions, as DPCPX did not modify the effect of WIN55,212-2 on 
[3H]glutamate release. Importantly, there was an attenuation of the 
effect of WIN55,212-2 in the presence of CPA, but there was no 
attenuation of the effect of CPA by WIN55,212-2. This suggests that 
the modulatory action of A1 over CB1 receptors is not reciprocal. 
 The A1-CB1 interaction was observed to occur at the level of G-
protein activation, as A1 receptor activation reduced the efficacy of 
both the full CB1 agonist WIN55,212-2 and partial CB1 agonist THC 
to stimulate [35S]-GTPγS binding in the hippocampus. A previous 
study observed that simultaneous application of CB1 and A1 (but not 
GABAB) agonists produced less than additive stimulation of [35S]-
GTPγS binding in cerebellar membranes, while long-term exposure 
to a CB1 agonist produced changes in A1 receptor signalling only at 
the level of adenylyl cyclase activity (Selley et al., 2004). Taken 
together, these data indicate that, under short periods of ligand 
exposure, the CB1-A1 receptor cross-talk occurs at the G-protein 
level, therefore upstream from adenylyl cyclase.  
 GABAB receptors are expressed in the same interneuron 
populations as CB1 receptors (Sloviter et al., 1999; Neu et al., 2007), 
where both couple to the Gαo1, Gαi2, Gαi3 subunits (Straiker et al., 
2002). However, CB1 receptor-mediated signalling, assessed either 
as inhibition of [3H]GABA release or stimulation of [35S]-GTPγS 
binding, were unaffected by GABAB receptor activation with the 
agonist baclofen. Since baclofen and CPA caused similar stimulation 
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of [35S]-GTPγS binding at the concentrations used, but only CPA was 
able to attenuate CB1 receptor signalling, one can conclude that the 
modulation of CB1 signalling by A1 receptors is not shared by all 
Gαi/o-coupled receptors. 
 Endogenous adenosine, by activating A1 receptors, regulates CB1-
mediated inhibition of glutamatergic synaptic transmission (Hoffman 
et al., 2010), though this interaction was not observed by others 
(Serpa et al., 2009), possibly due to the reasons discussed in section 
1.3. A1 receptors are mainly localized at glutamatergic neurons, while 
their presence in GABAergic neurons is much lower (Ochiishi et al., 
1999). In contrast, CB1 receptors are predominantly localized at the 
GABAergic neurons (see Mackie and Katona, 2009). Therefore, 
WIN55,212-2 induced stimulation of [35S]-GTPγS binding might be 
primarily derived from the activation of CB1 receptors at GABAergic 
neurons, though it is possible that a portion of the CPA-induced 
reduction in the efficacy of WIN55,212-2 was due to the influence of 
A1 receptors upon CB1 receptors at glutamatergic neurons.  
 Several examples of GPCR interactions are known to exist, one 
relevant interaction to the present work is the heteromeric complex 
between CB1 and A2A receptors in the striatum (Carriba et al., 2007). 
GPCR interactions constitute a physiologically relevant phenomenon 
(Milligan, 2008). These may be a result of G-protein sequestration 
(Vásquez and Lewis, 1999), convergent signalling to a shared 
effector (e.g. Pacheco et al., 1993; Selley et al., 2004), 
intramembrane receptor-receptor interactions (Fuxe et al., 2007), or 
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allosteric modulation (Milligan and Smith, 2007). Both A1 and CB1 
receptors interact with other GPCRs (Ferré et al., 2009; Sebastião 
and Ribeiro, 2009b), commonly through receptor heteromerization. 
The hypothesis of G-protein sequestration, as described for CB1 
receptors by Vásquez and Lewis (1999), is unlikely to occur for A1 
receptors because its inactivation by DPCPX did not improve the 
effect of WIN55,212-2 on [3H]GABA release.  
 The mechanisms of the interaction now reported may thus involve 
a cross-talk at the G-protein level, though a direct receptor-receptor 
interaction cannot be fully excluded. Prolonged treatment with 
agonists of the CB1 receptor induces the attenuation of effects 
mediated by the A1 receptor, and vice versa, both in the 
hippocampus (Kouznetsova et al., 2002) and cerebellum (DeSanty 
and Dar, 2001; Selley et al., 2004), leading to cross-tolerance. It is 
generally accepted that long-term exposure to CB1 agonists lead to 
its down-regulation (Tappe-Theodor et al., 2007). However, the 
hypothesis that heterologous receptor down-regulation occurred in 
our experimental conditions is unlikely since one study showed that 
long-term THC administration induced differences in A1-mediated 
inhibition of adenylyl cyclase, but not in activation of G-protein (Selley 
et al., 2004).  
 It is noteworthy that micromolar concentrations of CB1 
antagonists SR141716A and AM251 were found to inhibit A1 but not 
mACh or GABAB –mediated G-protein activation in cerebellar 
membranes (Savinainen et al., 2003), although the mechanism was 
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not investigated. While attempting to reduce basal G-protein activity 
in their assays, Savinainen et al. (2003) blocked the A1 tonic 
activation with DPCPX, thus improving signal-to-noise ratio of CB1 
agonist dose-response curves. However, this also indicated that A1 
receptors are not required for CB1 receptors to activate G-proteins in 
the cerebellum, e.g. unlike A2A-CB1 in the striatum (Carriba et al., 
2007; Tebano et al., 2009). In the hippocampus, the present work 
also shows that A1 receptor blockade does not prevent the effect of 
WIN55,212-2, further indicating that the A1-CB1 interaction has 
different characteristics from receptor-receptor heterodimers. 
 
 In conclusion, the findings reported in this chapter provide 
evidence of a functional A1-CB1 receptor interaction that is 
manifested at the level of G-protein activation in hippocampal 
neurons and that is relevant for the presynaptic regulation of GABA 
and glutamate release. 
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4.2. in vivo assessment of the effects of chronic 
caffeine administration upon the acute THC –induced 
spatial memory deficits in mice  
 
 The evidence that A1 receptor activation attenuates CB1 receptor 
signalling raised the hypothesis that this A1-CB1 interplay has a 
functional impact upon hippocampal-dependent memory. Both A1 
and CB1 receptors are the main targets for the cognitive effects of 
caffeine and THC (respectively), which represent two of the most 
heavily consumed psychoactive substances worldwide (Barone and 
Roberts, 1996; Leggett, 2006).  
 Since chronic caffeine consumption is known to induce an 
increase in adenosine A1, but not A2A receptors (reviewed by 
Jacobson et al., 1996), it represents an interesting model to study 
whether an increase in A1 receptors in the brain can impact upon the 
cognitive effects of acute THC administration.  
 Acute systemic THC administration induces CB1-dependent 
deficits in working memory (Varvel et al., 2001; Varvel and Lichtman, 
2002; Wise et al., 2009). I therefore used a hippocampal-dependent, 
short-term spatial memory testing protocol (Chen et al., 2000; 
Daumas et al., 2007; Daumas et al., 2008, see section 3.7.2), to 
study the effects of chronic caffeine administration on the memory 
deficits induced by an acute systemic THC injection in mice.  
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4.2.1. Characterization of the acute effects of THC in the ‘trials to 
criterion’ task 
 
 For the first set of experiments, the effect of THC (1-7 mg/kg), or 
vehicle (30 min before first trial), as well as the modification of this 
effect by AM251 (3 mg/kg, 15 min before THC, or vehicle), is 
displayed in Figure 4.2.1a-d. After completing the test with THC (task 
5), each subject rested for one day to allow for its metabolic 
clearance, then mice performed a control test (task 6) in which no 
acute drug was given, to measure whether performance levels 
returned to baseline values 48 hours after acute THC administration 
(see section 3.7.2. for further details). 
 
Table 4.2.1. F and p values from a repeated measures analysis of 
variance of all parameters measured, during the five training tasks 
(tasks 1-4) of the experiment shown in Figure 4.2.1. 
  Group Task Group × Task 
 
F 
(3,26) p 
F 
(3,78) p 
F 
(9,78) p 
Trials to 
criterion 1.01 0.408 72.7 <0.0001 0.35 0.79 
Latency 0.67 0.58 61.6 <0.0001 0.19 0.9 
Pathlength 0.39 0.765 52.6 <0.0001 0.09 0.964 
Average 
speed 0.11 0.955 1.83 0.15 0.66 0.744 
The significant p-values are underlined and highlighted in bold. The data 
shows no difference between groups, but a significant difference in values 
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between tasks, which indicates an improvement in performance on all 
parameters, except average swim speed. 
 
 During the training phase, all subjects learned to perform 
efficiently at all test parameters (see Figure 4.2.1a-c.). The number of 
trials, the total latency and total pathlength needed to reach the 
criterion, decreased progressively from task to task reaching a 
plateau in the last training task. A repeated measures 2-way analysis 
of variance (ANOVA) on these parameters revealed a significant 
overall learning effect (Table 4.2.1.). For ‘pathlength’ (Figure 4.2.1c, 
representative parameter of memory performance), significance 
values were F(3,78)=52.6, p<0.0001. The average swim speed 
(Figure 4.2.1d, control parameter for motor activity) was constant 
throughout the training tasks [F(3,78)=1.83 p=0.15] with no 
significant differences between groups [F(3,26)=0.11, p=0.96]. There 
were no differences between groups and no ‘grouptask’ interaction 
in any parameter during the training period (see Table 4.2.1.). 
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Figure 4.2.1. Dose-dependent effects of acute THC injection upon 
short-term spatial memory. (a-d) mice familiarized with the escape 
strategies during the first 4 tasks (training) and all groups showed improved 
performance in (a) the number of trials to reach criterion, (b) the escape 
latency, (c) swim pathlength, while (d) average swim speed remained 
constant. THC (1-7 mg/kg), or vehicle, was then tested in the absence (task 
5) and in the presence (task 7) of AM251 (3 mg/kg). Subjects rested for one 
day off drug after task 5, to allow full metabolization of THC. A control 
(CTR) test in the absence of acute drugs was performed at task 6 to 
measure whether performance levels returned to baseline values (see 
section 3.7.2. for details). For clarity of comparison between groups, 
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symbols were nudged at tasks 6 and 7. Note that acute THC induced 
spatial memory deficits at 3 mg/kg, and this effect of THC was fully 
prevented by previous administration of AM251. The effect of 7 mg/kg THC 
did not reach statistical significance. All drugs were given by i.p. injection. 
All data represent mean ± s.e.m. of n=7-8. *p<0.05, one-way analysis of 
variance, followed by Tukey post hoc test (see Table 4.2.2.). 
 
 There was a significant effect of THC on ‘latency’ (Figure 4.2.1b.) 
and ‘pathlength’ (Figure 4.2.1c.), but no significant effect on ‘average 
speed’ (Figure 4.2.1d.). The effects of THC on ‘latency’ and 
‘pathlength’ were only statistically significant at the dose of 3 mg/kg 
(p<0.05, Tukey post hoc, Table 4.2.2.). Although 7 mg/kg THC 
induced deficits in all parameters, except ‘average speed’, this effect 
did not reach statistical significance (p>0.05, Tukey post hoc).  
 The control (CTR) test, performed 48 h after the last THC 
injection, showed no significant effects of any treatment group on all 
parameters, indicating that the effects of THC were not prevailing 
after this period. When mice received AM251 pre-treatment, there 
were no significant effects of THC on all parameters, indicating that 
the moderate effects of THC were dependent on the activation of 
CB1 receptors.  
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Table 4.2.2. F and p values from one-way analysis of variance of all 
parameters measured during tasks 5-7 of the experiment shown in 
Figure 4.2.1. 
  Trials to 
criterion 
Latency Pathlength Average 
speed 
 
F 
(3,26) p 
F 
(1,26) p 
F 
(3,26) p 
F 
(1,26) p 
THC 2.36 0.096 3.08 0.047 3.29 0.038 0.25 0.86 
No 
drug 0.74 0.54 0.21 0.89 0.18 0.9 0.62 0.61 
THC 
+AM251 0.13 0.94 0.49 0.69 0.92 0.45 0.92 0.45 
 
The significant p-values are underlined and highlighted in bold. Note that 
there was a significant effect of THC on ‘latency’ and ‘pathlength’, and a 
marginally significant effect on ‘trials to criterion’, but no significant effect on 
‘average speed’. In the control (no drug) task, there were no significant 
effects any treatment group on all parameters. There were also no 
significant effects of THC, when AM251 was pre-administered. This 
indicates the effects of THC observed in task 5 were not preserved 48 h 
after administration, and that these effects are reversed by the blockade of 
CB1 receptors. See text for results of post hoc analysis. 
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4.2.2. Chronic caffeine administration increases acute THC–
induced spatial memory deficits in mice 
 
 Following the dose-response study, and in accordance other 
observations (Lichtman et al., 1995; Varvel et al., 2001; Wise et al., 
2009), a THC concentration of 5 mg/kg was selected for the 
subsequent tests, as it approaches the reported maximum selective 
effect, while not affecting motor activity.  
 For the second set of experiments, caffeine (3 mg/kg/day), or 
vehicle, was administered to mice >12 h before trials, and for at least 
15 days before the first test with THC. The effects of THC (5 mg/kg), 
or vehicle (30 min before first trial), as well as the modification of this 
effect by AM251 (3 mg/kg, 15 min before THC, or vehicle), are 
displayed in Figure 4a-d. After completion of the test task with THC 
(task 6), each subject rested for one day to allow for its metabolic 
clearance (see section 3.7.2. for further details). 
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Table 4.2.3. F and p values from a repeated measures analysis of 
variance of all parameters measured, during the five training tasks 
(tasks 1-5) of the experiment shown in Figure 4.2.2. 
 
  Group Task Group × Task 
 
F 
(3,25) p 
F 
(4,100) p 
F 
(12,100) p 
Trials to 
criterion 0.71 0.557 7.46 <0.0001 0.75 0.704 
Latency 0.42 0.739 10.17 <0.0001 0.55 0.878 
Pathlength 0.75 0.533 10.21 <0.0001 0.57 0.859 
Average 
speed 1.76 0.181 0.39 0.816 0.83 0.624 
 
The significant p-values are underlined and highlighted in bold. The data 
shows no difference between groups, but a significant difference in values 
between tasks, which indicates an improvement in performance on all 
parameters, except average swim speed. 
 
 During the training phase, all subjects learned to perform 
efficiently at all test parameters (see Figure 4.2.2a-c). The number of 
trials, the total latency and total pathlength needed to reach the 
criterion, decreased progressively from task to task reaching a 
plateau in the last training task. A repeated measures 2-way analysis 
of variance (ANOVA) on these parameters revealed a significant 
overall learning effect (Table 4.2.3.). For ‘pathlength’ (representative 
parameter of memory performance), significance values were 
F(4,100)=10.2, p<0.0001 (Figure 4.2.2c.). The average swim speed 
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(control parameter for motor activity) was constant throughout the 
training tasks [F(4,100)=0.4, p=0.8, Figure 4.2.2d.], with no 
significant differences between groups [F(3,25)=1.8, p=0.2]. In both 
sets of experiments, there were no differences between groups and 
no ‘grouptask’ interaction in any parameter during the training 
period (p>0.05 for all parameters). Thus, chronic caffeine 
administration by itself did not affect memory performance or motor 
activity. 
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  
Figure 4.2.2. Influence of chronic caffeine administration upon the 
THC-induced short-term spatial memory deficits. Caffeine was given 
daily (3 mg/kg, >12 h before trials), for 15 days before testing the effect of 
THC (see section 3.7.2.). (a-d) mice familiarized with the escape strategies 
during the first 5 tasks (training) and all groups showed improved 
performance in (a) the number of trials to reach criterion, (b) the escape 
latency, (c) swim pathlength, while (d) average swim speed remained 
constant. THC (5 mg/kg), or vehicle, was then tested in the absence (task 
6) and in the presence (task 7) of AM251 (3 mg/kg). Subjects rested for one 
day off drug after task 6, to allow full metabolization of THC. For clarity of 
comparison between groups, symbols were nudged at tasks 6 and 7. Note 
that chronic caffeine exacerbated the spatial memory deficits induced by 
acute THC, and this effect of THC was fully prevented by previous 
administration of AM251. All drugs were given by i.p. injection. All data 
represent mean ± s.e.m. of n=7-8. *p<0.05, 2-way analysis of variance, 
followed by Tukey post hoc test (see Table 4.2.4.).  
 
 As shown in Table 4.2.4, a 2-way ANOVA revealed a significant 
effect of THC on ‘trials to criterion’ [F(1,25)=4.24, p=0.05], ‘latency’ 
[F(1,25)=6.98, p=0.01], and ‘pathlength’ [F(1,25)=7.18, p=0.01], but 
no significant effect on ‘average speed’ [F(1,25)<0.001, p=0.98]. 
There were no effects of chronic caffeine treatment on all 
parameters, but a marginally significant ‘chronic caffeineTHC’ 
interaction on ‘pathlength’ [F(1,25)=3.11, p=0.09]. Whilst acute THC 
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injection (vs. vehicle) did not induce significant effects in the control 
(vehicle treated) group at any parameter, the effect of THC was 
exacerbated in the chronic caffeine group, on ‘latency’ (p=0.03, 
Tukey post hoc, Figure 4.2.2b.) and ‘pathlength’ (p=0.02, Tukey post 
hoc, Figure 4.2.2c.).  
 When mice received AM251 pre-treatment, there were no 
significant effects of any treatment group on all parameters, 
indicating that the effects of THC were dependent on the activation of 
CB1 receptors. These results show that chronic caffeine exacerbates 
the CB1-dependent actions of THC in a short-term spatial memory 
task. 
 
 
Table 4.2.4. F and p values from 2-way analysis of variance of all 
parameters measured during tasks 6 and 7 of the experiment shown 
in Figure 4.2.2. The significant p-values are underlined and highlighted in 
bold. Note that on task 6 there was a significant effect of THC on all 
memory parameters (‘trials to criterion’, ‘latency’ and ‘pathlength’), but no 
significant effect on ‘average speed’. On task 7 there were no significant 
effects of any treatment group on all parameters, indicating that the effects 
of THC observed in task 6 were dependent on the activation of CB1 
receptors. See text for results of post hoc analysis. 
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Task 7 
(+AM251) 
Task 6 
  
Interaction 
TH
C
 
C
affeine 
Interaction 
TH
C
 
C
affeine 
  
0.31 
1.26 
0.56 
0.75 
4.24 
0.19 
F 
(1,25) 
0.58 
0.27 
0.46 
0.39 
0.05 
0.67 
p 
Trials to 
criterion 
0.02 
1.16 
0.04 
2.46 
6.98 
0.73 
F 
(1,25) 
0.88 
0.29 
0.85 
0.13 
0.01 
0.40 
p 
Latency 
0.16 
1.09 
0.01 
3.11 
7.18 
1.47 
F 
(1,25) 
0.69 
0.31 
0.92 
0.09 
0.01 
0.24 
p 
P
athlength 
0.07 
0.09 
1.10 
1.41 
<0.001 
3.48 
F 
(1,25) 
0.79 
0.76 
0.31 
0.25 
0.98 
0.07 
p 
A
verage 
S
peed 
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4.2.3. Influence of chronic caffeine administration, and 
involvement of the adenosine A1 receptors, upon the acute 
effects of THC and WIN55,212-2 on short-term spatial memory  
 
 For the third set of experiments, caffeine (3 mg/kg/day), or 
vehicle, was administered to mice >12 h before trials, and for at least 
15 days before the first test with THC. The effect of THC (5 mg/kg), 
or vehicle (30 min before first trial), the modification of this effect by 
DPCPX (1 mg/kg, 15 min before THC, or vehicle), as well as the 
effect of WIN55,212-2 (1 mg/kg), or vehicle (30 min before first trial), 
are displayed in Figure 5a-d. After completion of each test task, 
subjects rested for one day off-drug to allow for metabolic clearance 
of THC. After completion of the test task with THC (task 5), there was 
a control test (task 6) in which no acute drug was given, to measure 
whether performance levels returned to baseline values 48 hours 
after acute THC administration (see section 3.7.2. for further details). 
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Table 4.2.5. F and p values from a repeated measures analysis of 
variance of all parameters measured, during the four training tasks 
(tasks 1-4) of the of the experiment shown in Figure 4.2.3. 
 
  Group Task Group × 
Task 
 
F 
(3,24) p 
F 
(3,72) p 
F 
(9,72) p 
Trials to 
criterion 0.08 0.968 15.22 <0.0001 1.63 0.122 
Latency 0.05 0.986 13.53 <0.0001 1.3 0.251 
Pathlength 0.03 0.994 13.52 <0.0001 1.32 0.24 
Average 
speed 0.2 0.892 1 0.397 0.42 0.918 
 
The significant p-values are underlined and highlighted in bold. The data 
shows no difference between groups, but a significant difference in values 
between tasks, which indicates an improvement in performance on all 
parameters, except average swim speed. 
 
 
 During the training phase, all subjects learned to perform 
efficiently at all test parameters (see Figure 4.2.3a-c). The number of 
trials, the total latency and total pathlength needed to reach the 
criterion, decreased progressively from task to task reaching a 
plateau in the last training task. A repeated measures 2-way analysis 
of variance (ANOVA) on these parameters revealed a significant 
overall learning effect. For ‘pathlength’ (representative parameter of 
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memory performance), significance values were F(3,72)=13.5, 
p<0.0001 (Figure 4.2.3c.). The average swim speed (control 
parameter for motor activity) was constant throughout the training 
tasks [F(3,72)=1, p=0.4, Figure 4.2.3d], with no significant differences 
between groups [F(3,24)=0.2, p=0.9]. In both sets of experiments, 
there were no differences between groups and no ‘grouptask’ 
interaction in any parameter during the training period (p>0.05 for all 
parameters). Thus, chronic caffeine administration by itself did not 
affect memory performance or motor activity. 
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Figure 4.2.3. Influence of chronic caffeine administration, and 
involvement of the adenosine A1 receptors, upon the acute effects of 
THC and WIN55,212-2 on short-term spatial memory. Caffeine was 
given daily (3 mg/kg, >12 h before trials), for 15 days before testing the 
effect of THC (see section 3.7.2.). (a-d) mice familiarized with the escape 
strategies during the first 4 tasks (training) and all groups showed improved 
performance in (a) the number of trials to reach criterion, (b) the escape 
latency, and (c) swim pathlength, while (d) average swim speed remained 
constant. THC (5 mg/kg), or vehicle, was tested in the absence (task 5) and 
in the presence (task 7) of DPCPX (1 mg/kg,). A control (CTR) test in the 
absence of acute drugs was performed at task 6 to measure whether 
performance levels returned to baseline values. Subjects rested for one day 
off drug after each test task, to allow full metabolization of THC. The effect 
of WIN55,212-2 (WIN, 1 mg/kg), or vehicle, was tested at task 8. For clarity 
of comparison between groups, symbols were nudged in tasks 5 to 8. Note 
that chronic caffeine exacerbated the spatial memory deficits induced by 
acute THC and WIN. The effect of THC was prevented by the previous 
administration of DPCPX. All drugs were given by i.p. injection. All data 
represent mean ± s.e.m. of n=7. *p<0.05, **p<0.01, 2-way analysis of 
variance, followed by Tukey post hoc tests (see Table 4.2.6.). 
 
 Consistent with the first set of experiments, there was a 
significant effect of THC (see Table 4.2.6.) on ‘trials to criterion’ 
[F(1,24)=6.34, p=0.02], ‘latency’ [F(1,24)=8.16, p=0.01], and 
‘pathlength’ [F(1,24)=9.19, p=0.01], but no significant effect on 
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‘average speed’ [F(1,24)=2.09, p=0.16]. On ‘pathlength’ there was 
also a significant effect of chronic caffeine treatment [F(1,24)=4.82, 
p=0.04], and a marginally significant ‘chronic caffeineTHC’ 
interaction [F(1,24)=3.29, p=0.08]. Whilst acute THC injection (vs. 
vehicle) did not induce significant effects in the control (vehicle 
treated) group at any parameter, the effect of THC was exacerbated 
in the chronic caffeine group, on ‘latency’ (p=0.02, Tukey post hoc, 
Figure 4.2.3b) and ‘pathlength’ (p=0.01, Tukey post hoc, Figure 
4.2.3c). There were also significant differences between THC on the 
chronic caffeine group vs. THC in the vehicle group on ‘pathlength’ 
(p=0.04); and between THC on the chronic caffeine group vs. the 
vehicle control group on ‘trials to criterion’ (p=0.05), ‘latency’ 
(p=0.01), and ‘pathlength’ (p=0.006).  
 When mice were tested 48 h after the last THC injection, there 
were no significant effects of any treatment group on all parameters, 
indicating that the effects of THC were not prevailing after this period 
(Table 4.2.6.). Importantly, when mice received a pre-treatment of 
DPCPX, there were also no significant effects of any treatment group 
on all parameters, indicating that the effects of THC were reversed 
by the blockade of A1 receptors (Table 4.2.6.).  
 Finally, there was a significant effect of WIN55,212-2 (see 
Table 4.2.6.) on ‘trials to criterion’ [F(1,24)=7.64, p=0.01], ‘latency’ 
[F(1,24)=7.50, p=0.01], and ‘pathlength’ [F(1,24)=7.74, p=0.01], but 
no significant effect on ‘average speed’ [F(1,24)=4.03, p=0.06]. The 
acute injection of WIN55,212-2 (vs. vehicle) did not induce significant  
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effects in the control (vehicle treated) group at any parameter, but its 
effects were exacerbated in the chronic caffeine group, on ‘latency’ 
(p=0.03, Tukey post hoc, Figure 4.2.3b) and ‘pathlength’ (p=0.03, 
Tukey post hoc, Figure 4.2.3c). There were also significant 
differences between WIN55,212-2 on the chronic caffeine group vs. 
the vehicle control group on ‘latency’ (p=0.03), and ‘pathlength’ 
(p=0.03). These findings show a significant chronic caffeine-induced, 
and A1 receptor-mediated, exacerbation of the CB1-dependent 
effects on short-term spatial memory. 
 
  
Table 4.2.6. F and p values from 2-way analysis of variance of all 
parameters measured during tasks 5 to 8 of the experiment shown in 
Figure 4.2.3. The significant p-values are underlined and highlighted in 
bold. Note that on task 5 there was a significant effect of THC on all 
memory parameters (‘trials to criterion’, ‘latency’ and ‘pathlength’), but no 
significant effect on ‘average speed’; on ‘pathlength’, there was also a 
significant effect of chronic caffeine, and a marginally significant interaction 
(Figure 4.3.3c). In task 6 and task 7 there were no differences between 
groups in any of the parameters, indicating that the effects of THC 
observed in task 5 were not preserved 48 h after administration, and that 
these effects are reversed by the blockade of adenosine A1 receptors. At 
task 8, there was a significant effect of WIN at the three memory 
parameters, but no significant differences between groups in ‘average 
speed’. See text for results of post hoc analysis. 
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4.2.4. Discussion 	  
 The results presented in this chapter describe the effects of THC 
in an ‘episodic-like’ short-term spatial memory task. The chronic 
administration of caffeine (3 mg/kg/day, for 15 days, >12 h before 
trials) did not by itself cause measurable effects, but led to an A1 
receptor-mediated exacerbation of the CB1-dependent acute effects 
of THC on short-term spatial memory. 	  
 Acute intraperitoneal THC administration disrupts hippocampal-
dependent memory through the activation of CB1 receptors (Wise et 
al., 2009) in GABAergic, but not glutamatergic, neurons 
(Puighermanal et al., 2009). Furthermore, the hippocampal circuits 
associated with ‘episodic-like’ memory are regulated by CB1 
receptors (Robbe and Buzsáki, 2009). The dose-response study 
performed to characterize the effects of THC in the ‘trials to criterion 
task’ showed significant CB1 receptor-mediated deficits in spatial 
memory induced by 3 mg/kg THC. This result is consistent with 
various reports of THC-induced deficits in spatial memory, in different 
testing paradigms (Lichtman et al., 1995; Varvel et al., 2001; Varvel 
and Lichtman, 2002; Varvel et al., 2005b; Niyuhire et al., 2007; Wise 
et al., 2009). However, this is the first description of the effects of 
THC using the ‘trials to criterion task’, which is sensitive to a 
hippocampal-dependent short-term, episodic-like spatial memory 
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(Chen et al., 2000; Daumas et al., 2007; Daumas et al., 2008). In this 
paradigm, mice are required to meet a much more rigorous 
performance criterion for successful completion of the task objectives 
(see section 3.7.2), and is therefore a more appropriate water maze 
paradigm to test mice, since mice are less competent in place and 
matching-to-place learning in water maze tasks, compared to rats 
(Whishaw and Tomie, 1996).  
 
 To evaluate the relevance of the cross-talk between A1 and CB1 
receptors in the hippocampus, a model of chronic intake of caffeine 
was used, since it is known to induce alterations in A1 receptor levels 
in the brain (Jacobson et al., 1996; present work). The dose of 
caffeine used (3 mg/kg/day) corresponds to approximately the 
average daily dose consumed by humans (Barone and Roberts, 
1996). A THC concentration of 5 mg/kg was selected for these tests, 
as it approaches the reported maximum selective effect, while not 
affecting motor activity (Lichtman et al., 1995; Varvel et al., 2001; 
Wise et al., 2009). Interestingly, the acute administration of 5 mg/kg 
THC in control (vehicle-treated) mice did not induce statistically 
significant deficits in performance. It has been reported that chronic 
handling in rodents can, by itself, induce long-term decreases in CB1 
receptors (Sciolino et al., 2010), and GABA receptors (Corda and 
Biggio, 1986), with measurable differences in the response of drugs 
acting at these targets (Brett and Pratt, 1990; Sciolino et al., 2010). 
Therefore, the differences in the effect of THC in naïve mice, 
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compared to its effect in chronic vehicle treated mice could be due to 
the extensive handling for chronic injection treatments that these 
groups of animals were subjected to.  
 
 Nevertheless, it was found that the chronic administration of a 
moderate dose of caffeine led to a consistent and significant A1 
receptor-mediated exacerbation of the disruptive effects of acute 
THC in short-term spatial memory. This effect appears to be opposite 
to what occurs upon acute administration of caffeine, since it was 
reported to antagonize the THC-induced changes in cortico-
hippocampal EEG wave recordings and locomotor activity (Consroe 
et al., 1976). In the present work, the acute co-administration of 
DPCPX in vehicle treated animals also did not increase the effects of 
THC. Moreover, the motor impairments induced by intracerebellar 
microinfusion of THC are enhanced by acute activation of A1 
receptors (Dar, 2000). It is known that chronic treatment with A1 
receptor ligands produces opposite behavioural effects from those 
observed following their acute administration. Indeed, there are 
frequent observations that chronic antagonist exposure causes 
similar actions to acute agonist exposure (Von Lubitz et al., 1993; 
Jacobson et al., 1996). It is noteworthy that behavioural tests were 
performed more than 12 h after administration of caffeine (i.p.). Since 
the half-life of caffeine for doses lower than 10 mg/kg ranges from 
0.7 to 1.2 h in the rat and mouse (see Fredholm et al., 1999), it is 
estimated that no relevant plasma concentrations of caffeine were 
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present at the time of THC administration. This might explain why 
acute caffeine administration prevents THC-induced effects (Consroe 
et al., 1976) whereas chronic caffeine exposure exacerbates the 
THC-induced memory disruption (present work).  
 The acute effect of the CB1 full agonist, WIN55,212-2, was also 
exacerbated in animals under chronic caffeine, which further 
validates the observations made with THC. However, despite 
statistically significant, the effect of WIN55,212-2 was of a lower 
magnitude than that of THC. This could be due to pharmacokinetic 
differences, since the quantity of WIN55,212-2 which penetrates 
brain tissue following i.p. injection is much lower than that of THC 
(Petitet et al., 1999). Higher doses of WIN55,212-2 were not used to 
avoid non-specific effects, as the systemic administration of 1 mg/kg, 
but not higher WIN55,212-2 doses, was previously demonstrated to 
have CB1-dependent effects on spatial memory without affecting 
motor activity (Varvel and Lichtman, 2002). 
 When given intraperitoneally, the low dose (1 mg/kg) of the A1 
receptor antagonist, DPCPX, used in the present study  has been 
shown to occupy A1 receptors (Baumgold et al., 1992; Hooper et al., 
1996), while not affecting motor activity (Von Lubitz et al., 1993). 
Accordingly, DPCPX fully prevented the acute effects of THC in the 
chronic caffeine group, while not having effects on performance in 
the absence of THC. This suggests that the activity of A1 receptors is 
not necessary for short-term spatial memory, but that chronic 
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caffeine-induced alterations to the effects of acute THC require A1 
receptor activation.  
 CB1 receptors form functional heteromeric complexes with A2A 
receptors in the striatum, and these complexes mediate the effects of 
cannabinoid agonists on locomotor activity and neuronal signalling in 
that brain region (Carriba et al., 2007; Tebano et al., 2009). 
Nevertheless, the involvement of A2A receptors in the THC-induced 
cognitive deficits following chronic caffeine consumption can be 
excluded given that the A1 antagonist DPCPX fully prevented these 
effects. Furthermore, both A1 and A2A receptors have similar affinities 
for caffeine (Fredholm et al., 1994), yet the expression of A2A 
receptors in the hippocampus and cortex is much lower than that of 
A1 receptors (reviewed by Ribeiro et al., 2002). Also, the levels of A2A 
receptors are not altered following chronic caffeine exposure and the 
development of tolerance to the motor and cognitive effects of 
chronic caffeine appears not to involve A2A receptors (Jacobson et 
al., 1996). 
 
 In summary, the results shown in this chapter provide the first 
evidence of chronic caffeine-induced modifications to the CB1 
receptor-mediated effects of THC in vivo. Furthermore, it is shown 
that A1 receptors have a specific role in mediating the exacerbated 
actions of THC induced by chronic caffeine. 
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4.3. In vitro characterization of the effects of chronic 
caffeine administration on A1 and CB1 receptor 
signalling 
 
 In the previous chapter, it was observed that chronic caffeine 
administration modified the CB1-dependent effects of both THC and 
WIN55,212-2 upon spatial memory, by inducing long-term adaptive 
changes in the brain that involved the A1 receptors. Following these 
observations, the neurochemical consequences of chronic caffeine 
administration were further investigated using the same dose and 
schedule of caffeine administration as for the behavioural 
experiments shown in the previous chapter. The subjects used were 
also mice of the same strain (C57Bl/6J) and age. 
 The influence of chronic caffeine administration upon A1 receptor 
number and affinity was first quantified by radioligand binding. The 
effects on CB1 receptor signalling were then investigated by 
comparing the effects of WIN55,212-2 and THC upon [3H]GABA 
release, and [35S]-GTPγS binding, between vehicle and chronic 
caffeine treated mice. Lastly, CB1 receptor number and affinity were 
quantified by radioligand binding, and Western blotting. 
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4.3.1. Chronic caffeine increases A1 receptor number in mouse 
cortico-hippocampal tissue 
 
 To quantify the influence of chronic caffeine administration upon 
A1 receptor number and affinity in cortico-hippocampal membranes, 
[3H]DPCPX (0.1-10 nM) binding assays were performed (Figure 
4.3.1.). In vehicle-treated mice, the total number of specific binding 
sites obtained by nonlinear regression analysis (Bmax) was 848 ± 44 
fmol/mg of protein, while the equilibrium dissociation constant (KD) 
was 1.20 ± 0.21 nM. In the chronic caffeine group, the Bmax was 
increased to 980 ± 50 fmol/mg of protein (p<0.05, n=6, vs vehicle 
group) but KD (1.31 ± 0.23 nM) was not significantly (p>0.05) 
affected. Thus, animals under chronic caffeine had ~16% higher 
density of A1 receptor without changes in affinity. 
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Figure 4.3.1. Saturation analysis of specific [3H]DPCPX binding (0.1-10 
nM) to cortico-hippocampal membranes (40 µg protein) from chronic 
caffeine (3 mg/kg/day, for 22 days,  ) and vehicle ( ) treated mice. Inset: 
Bmax obtained from non-linear regression analysis. Non-specific binding was 
determined at all [3H]DPCPX concentrations by addition of 2 µM XAC. All 
points represent mean ± s.e.m. of n=6, and each saturation experiment 
was performed in duplicate. *p<0.05, versus control, extra sum-of-squares 
F test of non-linear fit. 
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4.3.2. Chronic caffeine and CB1 receptor –dependent inhibition 
of [3H]GABA release from cortico-hippocampal synaptosomes 
 
 We first tested the consistency of our in vitro results between rats 
and mice by testing the effect of CPA (100 nM) on the WIN55,212-2–
mediated inhibition of K+-evoked [3H]GABA release from cortico-
hippocampal synaptosomes prepared from naïve mice (Figure 
4.3.2.). Consistent to previous observations in rats, the effect of 1 µM 
WIN55,212-2 alone was 19±1%, and it was significantly attenuated to 
9±1% in the presence of CPA (p<0.01, n=4, paired Student’s t-test, 
Figure 4.3.2.).  
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Figure 4.3.2. Influence of A1 receptor activation on the WIN55,212-2 
(WIN)-mediated inhibition of [3H]GABA release from mouse cortico-
hippocampal synaptosomes. (a,b) Average fractional release of 
[3H]GABA from one set of experiments, showing  the effect of 1 µM WIN in 
the absence (a), or in the presence (b) of CPA (100 nM). (c) Histogram 
representing the effects as percentage inhibition of [3H]GABA release. Note 
that, as observed in rats, CPA significantly attenuated the inhibition induced 
by 1 µM WIN (**p<0.01). All data represent the mean ± s.e.m. of 4 
experiments performed in duplicate. The S2/S1 values from corresponding 
controls were taken as 0% within each experiment (see section 3.4.1. for 
further details). P-value was obtained by paired Student’s t-test, compared 
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to the effect of THC in absence of CPA within the same batch of 
synaptosomes. 
 
 
 The influence of chronic caffeine administration upon the CB1 
receptor-mediated inhibition of K+-evoked [3H]GABA release was 
then analyzed (Figure 4.3.3.). In control (vehicle-treated) mice, 1 µM 
WIN55,212-2 inhibited [3H]GABA release by 17±1%, while in the 
chronic caffeine group, the effect was significantly reduced to 11±2% 
(p<0.05, n=4, Figure 4.3.3a,c,e.). As observed in rats (Figure 4.1.6.), 
and in naïve mice (Figure 4.3.2.), the effect of WIN55,212-2 in the 
presence of CPA (100 nM) was significantly reduced (11±2%, 
p<0.05, n=6, 4.3.3b,e.) in control mice. This attenuation was of the 
same magnitude as the decrease observed in the chronic caffeine-
treated group in the absence of CPA (Figure 4.3.3c,e). In the chronic 
caffeine group, CPA still caused a small decrease in the effect of 
WIN55,212-2, though it did not reach statistical significance (7±2%, 
p>0.05, n=6, Figure 4.3.3d,e). This may suggest that chronic caffeine 
treatment leads to a long lasting disturbance of CB1 receptor 
signalling, and that a further activation of A1 receptors does not have 
additive effects upon the modification of CB1 receptor signalling. 
These results are therefore in accordance with the hypothesis that 
chronic caffeine and acute A1 receptor activation share common 
mechanisms. 
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  
Figure 4.3.3. Influence of chronic caffeine, and A1 receptor activation 
on the WIN55,212-2 (WIN)-mediated inhibition of [3H]GABA release 
from mouse cortico-hippocampal synaptosomes. (a,d) Average 
fractional release of [3H]GABA from two sets of experiments, showing the 
effect of 1 µM WIN in the absence (a,c) or in the presence (b,c) of CPA 
(100 nM), both in control (vehicle-treated) (a,b), or in chronic caffeine 
treated mice (c,d), as indicated. Data represents the mean ± s.e.m. of n=4 
(a,c) or n=6 (b,d), performed in duplicate, in each experiment, a batch of 
synaptosomes from control (vehicle-treated) animals and a batch from 
chronic caffeine treated animals was used in parallel. (e) Histogram 
representing the effects as percentage inhibition of [3H]GABA release. Note 
that CPA significantly attenuated the inhibition induced by 1 µM WIN in the 
control group (*p<0.05), but not in chronic caffeine group. The effect of WIN 
in the chronic caffeine treated group was also reduced (*p<0.05). All data 
represent the mean ± s.e.m. of 4 experiments performed in duplicate. The 
S2/S1 values from corresponding controls were taken as 0% within each 
experiment (see section 3.4.1. for further details). P-value was obtained by 
unpaired Student’s t-test, compared to corresponding controls. 
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 The effects of the partial CB1 agonist THC were then compared 
between control (vehicle-treated) and chronic caffeine treated mice, 
in the absence or in the presence of CPA (Figure 4.3.4.). THC (1 µM) 
inhibited [3H]GABA release by 11±2% in the control group, and by 
9±3% in the chronic caffeine group (p>0.05, n=7, Figure 4.3.4a,c,e). 
In the presence of CPA (100 nM), the effect was not significantly 
modified either in control (10±2%, p>0.05, n=7, Figure 4.3.4b,e), or in 
chronic caffeine treated mice (7±2%, p>0.05, n=7, Figure 4.3.4d,e).  
 The effect of THC was of a similar magnitude as that observed in 
rat hippocampal synaptosomes, where there was also no influence of 
CPA (Figure 4.1.7.). The absence of attenuation of its effect by 
chronic caffeine or CPA may be due to the small magnitude of its 
effect in vitro that could represent a below-threshold population of 
CB1 receptors under modulatory control of A1 receptors, as observed 
in Figure 4.1.7, and discussed in section 4.1.5. 
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Figure 4.3.4. Influence of chronic caffeine, and A1 receptor activation 
on the THC-mediated inhibition of [3H]GABA release from mouse 
cortico-hippocampal synaptosomes. (a,d) Average fractional release of 
[3H]GABA from two sets of experiments, showing the effect of 1 µM THC in 
the absence (a,c) or in the presence (b,c) of CPA (100 nM), both in control 
(vehicle-treated) (a,b), or in chronic caffeine treated mice (c,d), as 
indicated. Data represents the mean ± s.e.m. of n=7 (a-d) performed in 
duplicate, in each experiment, a batch of synaptosomes from control 
(vehicle-treated) animals and a batch from chronic caffeine treated animals 
was used in parallel. (e) Histogram representing the effects as percentage 
inhibition of [3H]GABA release. Note that neither CPA nor chronic caffeine 
treatment significantly modified the effect of THC (p>0.05). All data 
represent the mean ± s.e.m. of 7 experiments performed in duplicate. The 
S2/S1 values from corresponding controls were taken as 0% within each 
experiment (see section 3.4.1. for further details). P-value was obtained by 
unpaired Student’s t-test, compared to corresponding controls. 
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4.3.3. Chronic caffeine and CB1 receptor -dependent stimulation 
of G-proteins in cortico-hippocampal membranes  
 
 To evaluate whether the influence of chronic caffeine 
administration upon CB1 signalling was manifested at the level of G-
protein activation, we measured agonist-stimulated [35S]-GTPγS 
binding in cortico-hippocampal membranes prepared from control 
(vehicle treated) or chronic caffeine treated mice, in absence and in 
the presence of A1 receptor agonist CPA.  
 As Figure 4.3.5 and Table 4.3.1 show, in cortico-hippocampal 
membranes of vehicle-treated mice, WIN55,212-2 stimulated [35S]-
GTPγS binding (% of basal) with an EC50 ≈989 nM and 
Emax=321±11% (n=5, Figure 4.3.5a), while THC had an EC50 ≈41 nM 
and Emax=167±11% (n=4, Figure 4.3.5c). Chronic caffeine 
administration did not affect the EC50 of WIN55,212-2 or THC, but it 
significantly reduced the Emax of WIN55,212-2 to 269±8%, and of 
THC to 135±8% (p<0.05, n=4-5, Figure 4.3.5a,c). As observed in rats 
(Figure 4.1.10a), the co-application of 100 nM CPA in control mice 
significantly decreased the Emax of WIN55,212-2 (254±13%, p<0.05, 
n=5, Figure 4.3.5b), but not the EC50. The reduction in WIN55,212-2-
stimulated [35S]-GTPγS binding, caused by CPA in membranes from 
control animals, was of similar magnitude as the decrease observed 
in the chronic caffeine-treated group in the absence of CPA (Table 
4.3.1.).  
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Figure 4.3.5. Effect of chronic caffeine on the stimulation of cortico-
hippocampal [35S]GTPγS binding by CB1 agonists. Cortico-hippocampal 
membranes (10 µg protein) from chronic caffeine ( , ) and vehicle ( , 
 ) treated mice were incubated for 30 min at 37o C with 30 µM GDP, 0.1 
nM [35S]GTPγS and varying concentrations of WIN (0.1 nM-10 µM) alone 
(a), or in presence of 100 nM CPA (b); and of THC (0.1 nM – 1 µM) alone 
(c), or in presence of 100 nM CPA (d). All Emax and log EC50 values are 
shown in Table 4.3.1. Data represent mean percentage of basal stimulation 
± s.e.m. of, n=5 (a,b), n=4 (c), and n=5 (d), performed in duplicate. Non-
visible error bars are within symbols. 
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 In the chronic caffeine group, CPA did not induce a further 
decrease in the efficacy of WIN55,212-2 to stimulate G-protein 
activation (Emax=252±8%, Figure 4.3.5a,b), which may suggest that 
chronic caffeine treatment and A1 receptor activation do not have 
additive effects upon the modification of CB1 receptor signalling, 
therefore sharing common mechanisms. However, CPA did not 
significantly reduce the Emax of THC in the control group (146±13%, 
p>0.05, n=4) or in the chronic caffeine group (130±12%, p>0.05, 
n=4). CPA also did not significantly affect the EC50 of THC, in any 
group (p>0.05, n=4, Table 4.3.1). So, it appears that the effect of a 
partial agonist is much less altered by A1 receptor activation than that 
of a full agonist. 
  The basal [35S]GTPγS binding in the absence of WIN55,212-2 
(Figure 4.3.5a,b) or THC (Figure 4.3.5c,d) is represented as 100% in 
the ordinates, which corresponds to (fmol/mg protein): Figure 
4.3.5a,b: 143 ± 10 ( , n=5), 154 ± 15 ( , n=5), 324 ± 13 ( , n=5), 
and 327 ± 25 ( , n=5); Figure 4.5.3c,d: 53 ± 9 ( , n=4), 67 ± 10 ( , 
n=4), 121 ± 17 ( , n=5), and 150 ± 21 ( , n=5).  
 CPA (100 nM), by itself, enhanced [35S]-GTPγS binding by 
122±9% (over 2 fold net increase from basal binding) in membranes 
prepared from vehicle-treated subjects, and by 111±7% in the 
chronic caffeine group (p>0.05, n=5, data not shown), hence the 
ability of A1 receptors to activate G-proteins is unaltered in chronic 
caffeine treated mice. Accordingly, there were no statistically 
significant differences in the bottom of the non-linear regression 
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binding curves between chronic caffeine and vehicle treated animals, 
in the presence of CPA (p>0.05, n=5, Figure 4.3.5b,d). 
A1-­‐CB1	  receptor	  interplay	  in	  the	  hippocampus	  
	  144	  
 
Table 4.3.1. Emax and log EC50 values of WIN55,212-2 (WIN) and THC-
stimulated [35S]GTPγS binding in mouse cortico-hippocampal 
membranes. 
 
 
 
 
 
 
 
 
 
 
 
Note that the Emax, but not the EC50, of WIN and THC-stimulated 
[35S]GTPγS binding was significantly decreased in the chronic caffeine 
group (3 mg/kg/day, for 22 days), compared to control (vehicle treated) 
mice. The A1 receptor agonist, CPA (100nM) reduced the Emax of WIN, in 
control mice, but did not further decrease the Emax of WIN in chronic 
caffeine treated mice. CPA did not significantly reduce the Emax of THC, or 
the EC50 of WIN and THC, in the control group or in the chronic caffeine 
group (p>0.05, extra sum-of-squares F test). Data represent mean values ± 
s.e.m (n=4-5) obtained from nonlinear regression analyses of the data 
shown in Figure 4.3.5. *p<0.05, versus corresponding control, calculated 
using the extra sum-of-squares F test.  
  EC50 Emax 
  -log, M % of stimulation 
WIN  -6.005 ± 0.09 321 ± 11 
WIN + CPA  -5.654 ± 0.16   254 ± 13 * 
THC  -7.389 ± 0.37 167 ± 11 V
eh
ic
le
 
THC + CPA  -8.060 ± 0.69 146 ± 13 
WIN  -6.006 ± 0.08 269 ± 8 * 
WIN + CPA  -6.035 ± 0.10 252 ± 8 * 
THC  -7.660 ± 0.56 135 ± 8 * C
hr
on
ic
 
ca
ffe
in
e 
THC + CPA  -7.979 ± 0.84 130 ± 12 
Results	  and	  discussion	  
	   145	  
 
4.3.4. Chronic caffeine and CB1 receptor number in mouse 
cortex and hippocampus 
 
 The effects of chronic caffeine administration upon CB1 signalling 
in vitro suggested that CB1 receptor number and/or affinity are 
decreased in these mice. The effect of chronic caffeine 
administration in CB1 receptor number and affinity was first analyzed 
by performing [3H]SR141716A (0.1 – 4 nM) saturation binding assays 
in tissue collected from mice used in the behavioral experiments.  
 The non-linear regression analysis of [3H]SR141716A binding to 
cortical membranes of vehicle treated mice showed a 
Bmax=1425±123 fmol/mg of protein, and a KD=1.4 ± 0.3 nM (n=10, 
Figure 4.3.6a). In hippocampal membranes, the Bmax of 
[3H]SR141716A was 1322 ± 97 fmol/mg of protein, and the KD=1.0 ± 
0.2 nM (n=5, Figure 4.3.6b). In the chronic caffeine group, the Bmax of 
[3H]SR141716A binding was lower (p<0.05, compared to vehicle 
group) and this reduction was observed both in cortical membranes 
(Bmax=1151 ± 65 fmol/mg of protein, n=10) and hippocampal 
membranes (Bmax=1089 ± 57 fmol/mg of protein, n=5). There were 
no significant differences in affinity, as in the chronic caffeine group, 
the KD values for [3H]SR141716A binding were 1.0 ± 0.2 nM in 
cortical, and 0.9 ± 0.1 nM in hippocampal membranes. 
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Figure 4.3.6. Saturation analysis of specific [3H]SR141716A binding 
(0.1 – 4nM) to (a) cortical and (b) hippocampal membranes (50 µg protein) 
from chronic caffeine (3 mg/kg/day, for 22 days), and vehicle treated mice. 
Insets: Bmax values, obtained from non-linear regression analysis. Non-
specific binding was determined at all [3H]SR141716A concentrations by 
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addition of 1 µM AM251. All points represent mean ± s.e.m. of 5-10 
experiments, each performed in duplicate. *p<0.05, versus control, extra 
sum-of-squares F test of non-linear fit. 
 
 
 
 A quantification of CB1 receptors in cortico-hippocampal 
membranes was also performed by Western blot analysis. As shown 
in Figure 4.3.7, the density of CB1 receptors from chronic caffeine 
treated (3 mg/kg/day, for 22 days) mice was 33±20% lower, 
compared to vehicle treated (p=0.06, Student’s t-test). Despite a 
marginal statistical significance, this reduction in CB1 receptor 
density is consistent with the observations from the [3H]SR141716A 
binding experiments (Figure 4.3.6).  
 These findings indicate that the chronic exposure to a moderate 
dose of caffeine significantly reduced the number of CB1 receptors in 
cortical and hippocampal membranes. 
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Figure 4.3.7. Influence of chronic caffeine administration on CB1 
receptor density in cortico-hippocampal membranes. (a) Membrane 
tissue prepared from chronic caffeine (3 mg/kg/day, for 22 days, n=8), or 
vehicle (n=9), treated mice was lysed, immunoblotted and probed for CB1 
and tubulin, as indicated. (b) Densiometry quantification of CB1 staining 
normalized by tubulin in the control (vehicle) and chronic caffeine group. 
100% corresponds to average CB1 staining in the vehicle treated group 
(n=9). Data represents mean ± s.e.m. of samples from 9 (vehicle treated) 
or 8 (chronic caffeine treated) individual mice immunoblotted in the same 
experiment. Note that there was a marginally significant (p=0.06, Student’s 
t-test) decrease in the density of CB1 receptors in the chronic caffeine 
group. This decrease is consistent with the observed diminution of 
a 
b 
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[3H]SR141716A Bmax in cortical and hippocampal membranes (Figure 
4.3.6.). 
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4.3.5. Discussion 	  
 In the present chapter, it was shown that a moderate dose of 
caffeine (3 mg/kg/day), administered chronically for 22 days, induces 
a significant increase in A1 receptors, while it also leads to a 
consistent decrease in CB1 receptors. Furthermore, CB1 signalling, 
as measured by agonist-induced inhibition of [3H]GABA release, or 
[35S]GTPγS binding, was significantly reduced in chronic caffeine 
treated mice, compared to vehicle-treated mice. These observations 
in vitro do not linearly reflect the effects observed in vivo (chapter 
4.2). However, the observations from both approaches should not be 
considered mutually exclusive (see chapter 5). 
 
 Since A1 and CB1 receptors are also densely expressed in the 
cortex, cortico-hippocampal preparations from mice were used in 
these experiments to yield the maximum amount of sample content 
with a minimum use of animals, in accordance with ethical 
guidelines. 
 The dose of caffeine administered to mice in the present work is 
equivalent to the estimated US average human daily caffeine 
consumption from all dietary sources (Barone and Roberts, 1996) 
and it led to a ~16% increase in cortico-hippocampal A1 receptors. 
This is the first description of alterations in A1 receptors induced by 
chronic administration of such a low dose of caffeine. 
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  The increase in A1 receptor levels that occurs after chronic 
caffeine administration, is attributed to the prevention of receptor 
down-regulation caused by tonic activation by endogenous 
adenosine (see Fredholm et al., 1999). However, exposure to high 
doses of caffeine (about 100 mg/kg/day) also leads to increased 
brain levels of other receptors, namely 5-HT, acetylcholine, GABAA 
and opioid receptors, as well as L-type Ca2+ channels, while β-
adrenoceptors are down-regulated (Shi et al., 1993, 1994).  
 
 The consistency of the in vitro results between rats (chapter 4.1) 
and mice (present chapter) was confirmed, as the effect of 
WIN55,212-2-mediated inhibition of [3H]GABA release, from cortico-
hippocampal synaptosomes prepared from naïve mice, was 
significantly attenuated by CPA. However, some differences in the 
EC50 and Emax of WIN55,212-2 were observed between species 
(Figures 4.1.10, 4.3.5). Since agonist efficacy is critically dependent 
on GDP concentration (Breivogel et al., 1998; Savinainen et al., 
2001), these differences could be due to small variations in signal-to-
noise ratio (i.e. agonist-stimulated to basal [35S]GTPγS binding ratio) 
of the assays, between hippocampal preparations from the rat and 
cortico-hippocampal preparations from the mouse. Nevertheless, the 
effect of WIN55,212-2 upon [3H]GABA release from mouse cortico-
hippocampal synaptosomes (Figure 4.3.2) was of the same 
magnitude as that observed in rats (Figure 4.1.6), showing that there 
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are no differences in CB1 receptor-dependent inhibition of GABA 
release between both species. 
 
 The effect of WIN55,212-2 on [3H]GABA release, as well as the 
Emax of WIN55,212-2 stimulated [35S]GTPγS binding, were 
significantly reduced in the chronic caffeine treated group. This 
reduction was of the same magnitude as that observed in the 
vehicle-treated group, in the presence of CPA. However, since the 
tonic activation of A1 receptors was prevented through elimination of 
endogenous adenosine by vertical superfusion in the release assays, 
and by ADA in the binding assays, it is unlikely that a chronic 
caffeine-induced increase in A1 receptor levels could be responsible 
for reduction of these CB1-dependent actions. Moreover, there was 
no further CPA-induced attenuation of the effect of WIN55,212-2 in 
the chronic caffeine group, which may indicate that the chronic 
caffeine-induced changes, and the activation of A1 receptors do not 
have additive effects upon CB1 receptor signalling.  
 As observed in rat tissue (Figure 4.1.7), activation of A1 receptors 
by CPA in control (vehicle-treated) mice did not attenuate the low 
inhibition of [3H]GABA release induced by THC. Similarly, the effect 
of THC on [3H]GABA release was unchanged by chronic caffeine 
exposure. In the vehicle-treated group, the Emax of THC in stimulation 
of [35S]GTPγS binding was unaltered in the presence of CPA, 
however it was significantly reduced in the chronic caffeine group. 
This may indicate the efficacy of THC was mostly affected by chronic 
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caffeine-induced changes in A1 and CB1 receptors at the 
glutamatergic neurons. Therefore, as discussed in section 4.1.5, the 
effects of THC, as a partial agonist, may not represent a measurable 
quantity of the CB1 signalling that is affected by A1 receptors. 
 
 Quantification of CB1 receptors, both by radioligand binding and by 
Western blotting, revealed a ~19% decrease of CB1 receptors in 
cortical and hippocampal tissue of chronic caffeine treated mice. 
Since the dose of caffeine that was administered was adenosine 
receptor selective, it is likely that chronic caffeine intake, by inducing 
an imbalance in A1 receptors, may have disturbed the A1-CB1 cross-
talk, and thus induced adaptive changes in CB1 receptor expression.  
 In a recent study, the chronic administration of a high dose of 
caffeine (210 mg/kg/day) in rats was shown to potentiate CB1-
dependent effects at striatal GABAergic, but not glutamatergic, 
synapses (Rossi et al., 2009). The mechanisms behind these effects 
of chronic caffeine were not explored and it is difficult to draw a 
comparison to the present study, given the differences in the 
experimental approach. It must be noted that the concentrations of 
caffeine used in most studies reporting changes in the levels of non-
adenosinergic receptor systems are more than 30 times higher than 
the equivalent to the daily human intake and are not adenosine 
receptor-selective. These concentrations of caffeine may therefore 
have induced alterations via inhibition of phosphodiesterases and 
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blockade of GABAA receptors, among others (see Daly and 
Fredholm, 1998).  
 
 In summary, the findings in the present chapter shown that chronic 
caffeine treatment leads to a reduction in cortical and hippocampal 
CB1 receptor number. There was a corresponding attenuation of CB1 
signalling in vitro. Although the exact mechanisms that link chronic 
caffeine administration to a reduction in CB1 receptor number and 
signalling were not characterized in this study, this is the first 
description of chronic caffeine-induced changes to the expression of 
CB1 receptors, and their signalling. 
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5. General discussion 
 
 Given that the activation of A1 receptors inhibited the CB1-
mediated actions in the ex vivo and in vitro assays (chapter 4.1 and 
4.3), it would be expected that chronic caffeine, by increasing A1 
receptor levels, would attenuate the cognitive-disrupting effects of 
THC. Surprisingly, the effects of THC were exacerbated by an A1 
receptor-mediated mechanism (chapter 4.2) and, interestingly, this 
occurred in spite of a significant reduction in CB1 receptors (chapter 
4.3). Therefore, the changes observed ex vivo and in vitro do not 
linearly reflect the effects upon the integrated hippocampal circuitry in 
vivo, and this apparent discrepancy must be given careful 
consideration.  
 Each approach provides a piece of evidence that should not be 
considered mutually exclusive. The results of both the ex vivo and 
the in vitro approach provide an analysis of the phenomena occurring 
at the level of the receptor signalling and their effects on 
neurotransmitter release, from distinctive populations of nerve 
terminals. In addition, they also show that chronic caffeine 
administration interferes with the expression levels of A1 and CB1 
receptors, which have important roles in the hippocampal circuitry. It 
cannot however be assumed that the full extent of the chronic 
caffeine-induced alterations to the hippocampal circuitry of a live 
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functioning animal should strictly reflect the changes observed in an 
ex vivo or in vitro model. 
 Thus, the sensitization to the effects of THC by chronic caffeine 
was possibly a consequence of an imbalance in GABAergic 
transmission resulting from alterations in A1 and CB1 levels. Chronic 
exposure to high doses of caffeine leads to an increase in GABAA 
and opioid receptors (Shi et al., 1993, 1994). These receptors are 
also important players in perisomatic inhibition at the hippocampal 
pyramidal cells (Hoffman and Lupica, 2000; Glickfeld et al., 2008). 
Since the adenosine receptor-selective dose of caffeine used in the 
present work significantly affected a non-adenosinergic receptor 
(CB1), it cannot be excluded that other receptor systems were also 
affected by a perturbation in synaptic transmission.  
 One likely hypothesis that emerges is that these alterations also 
led to adaptive changes in GABAA receptors at the pyramidal cells 
and/or (less likely) other receptors at the parvalbumin-expressing 
(PV) GABAergic neurons, which do not express CB1 receptors 
(Katona et al., 1999). 
 Exogenous and endogenous cannabinoid agonists inhibit the 
GABAA, but not GABAB, receptor-dependent inhibition of pyramidal 
postsynaptic currents (Hoffman and Lupica, 2000; Lafourcade and 
Alger, 2008). Therefore, GABA released from the CCK-expressing 
GABAergic interneurons (that contain CB1 receptors) selectively 
activates GABAA receptors in the pyramidal neurons and the 
inhibition of this process by CB1 receptor agonists results in cognitive 
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disruption. Accordingly, blockade of GABAA receptors reverses the 
cognitive effects of acute THC in vivo (Varvel et al., 2005b).  
 Although the GABAergic circuitry is heavily implicated in the 
amnesic effects of THC (Robbe et al., 2006; Puighermanal et al., 
2009; Robbe and Buzsáki, 2009), the activity of both PV and CCK-
expressing basket cell populations is mostly under control of 
glutamatergic input (see Freund and Buzsáki, 1996; Freund and 
Katona, 2007). Thus, the role of glutamate modulation should also be 
taken into account. The A1-CB1 interaction is relevant for the 
modulation of excitatory synaptic transmission in the hippocampus 
(Hoffman et al., 2010, confirmed in the present work), and chronic 
caffeine administration may thus have hindered CB1-mediated 
modulation of glutamate release. Given that the expression of CB1 
receptors at glutamatergic neurons is already approximately 20 times 
lower than at GABAergic neurons (Katona et al., 2006; Kawamura et 
al., 2006; Mackie and Katona, 2009), this could have contributed to a 
sensitization of the circuitry to the effects of THC at the GABAergic 
neurons. 
 There is a functional dichotomy between PV and CCK-expressing 
basket cells associated with the connectivity and expression profile 
for receptors, transmitters and modulators (Glickfeld and Scanziani, 
2006; Freund and Katona, 2007; Klausberger and Somogyi, 2008). 
The PV-containing basket cells are driven by local principal cells, and 
are fast responders to their modulatory input (reviewed by Freund 
and Katona, 2007). The CCK-containing basket cells mostly receive 
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input from subcortical neurons and modulate synchronous pyramidal 
ensemble activity after integrating input signals over longer time 
windows (reviewed by Freund and Katona, 2007). Synchronous firing 
of pyramidal cells is under fine control of CB1 receptor-mediated 
modulation of GABA release (Hájos et al., 2000; Robbe et al., 2006; 
Goonawardena et al., 2010), and is a key mechanism for memory 
function (Robbe and Buzsáki, 2009).  
 Assuming that chronic caffeine not only affected A1 and CB1 
receptors, but also led to an increase in GABAA receptors (Shi et al., 
1993), it would result in an enhanced sensitivity of the circuit to the 
fast spiking activity of PV cells. Thus, a critical imbalance in the 
temporal coordination of pyramidal cell firing might have become 
evident by the administration of THC, as pyramidal cells would then 
mostly respond to the oscillating GABA released from PV cells, 
hence leading to increased inhibition of pyramidal cell firing.  
 Since DPCPX effectively prevented the THC-induced deficits, it is 
most likely that this prevention reflects the blockade of inhibitory 
tonus upon excitatory transmission in the hippocampal circuitry. A1 
receptor levels were increased after chronic caffeine exposure, 
therefore there might be an enhanced adenosinergic inhibitory tonus 
under these conditions. Thus, blockade of A1 receptors may have 
equilibrated the activity levels of the pyramidal cells and, through this 
mechanism, led to the prevention of THC-induced memory deficits. 
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6. Conclusions 	  
 The work presented in this thesis provides evidence that an A1-
CB1 receptor interaction has relevant consequences to the function 
of the hippocampus which impact upon the behavioural interaction 
between two of the most widely consumed psychoactive drugs: 
caffeine and THC. 
 
 I demonstrated that adenosine A1 receptors located in GABAergic 
and glutamatergic presynaptic nerve terminals of the hippocampus 
exert a negative modulatory effect on the cannabinoid CB1-mediated 
inhibition of GABA and glutamate release. 
 
 I showed that this interaction occurs at the level of G-protein 
activation.  
 
 In addition, I demonstrated that chronic administration of caffeine 
leads to an A1 receptor-mediated exacerbation of the CB1-dependent 
effects of THC on short-term spatial memory. 
 
 I also showed that chronic caffeine treatment induces a reduction 
in cortical and hippocampal CB1 receptor number and attenuation of 
signalling ex vivo and in vitro, while inducing an increase in A1 
receptors. 
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 These findings provide the first evidence of chronic caffeine-
induced alterations in cannabinoid signalling in the cortex and 
hippocampus. The results obtained suggest that chronic caffeine 
consumption, probably by inducing an increase in total A1 receptor 
numbers, led to an imbalance of the hippocampal inhibitory circuit, 
which led to an exacerbation of the cognitive disrupting actions of 
CB1 receptor agonist. 
  In summary, the present work highlights two relevant factors 
influencing cannabinoid CB1 signalling in the hippocampus: the 
activity of A1 receptors, and the chronic consumption of caffeine.  
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7. Future perspectives 	  
 The characterization of the endocannabinoid system has only 
emerged during the last two decades and it quickly became well 
established as a key regulator of mammalian neuronal and cellular 
activity in various body tissues, but with particular importance to the 
central and peripheral nervous system (Marsicano and Kuner, 2008). 
Still, many physiological and pharmacological aspects of its actions 
remain uncharacterized and it remains a very attractive subject in 
neuroscience. Cannabinoid-based therapies are already currently 
used as alternative antiemetic, appetite stimulant, antispasmodic and 
analgesic treatments (Di Marzo and Petrocellis, 2006).  
 There is potential for the development of cannabinoid-based 
therapies for Alzheimer’s disease (Ceballos, 2008), Epilepsy (Monory 
and Lutz, 2008), and schizophrenia (Köfalvi and Fritzsche, 2008; 
Parolaro et al., 2010). In the hippocampus, CB1 receptor-mediated 
regulation of neurotransmitter release is not only critical for memory 
function (Puighermanal et al., 2009) but also for neuroprotection (e.g. 
Monory et al., 2006), an action shared by A1 receptors (de Mendonça 
et al., 2000). Moreover, the importance of the endocannabinoid 
system in hippocampal-dependent functions presents a fascinating 
route for the pursuit of cognitive enhancing therapies.  
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 The A1-CB1 receptor interaction identified in the present study 
therefore points towards the possibility that the pathophysiologic or 
therapeutically relevant actions operated by CB1 receptors can be 
significantly affected by interference with A1 receptor activity, as is 
the case of chronic caffeine intake. Extracellular levels of both 
adenosine and endocannabinoids are increased in deleterious 
situations for neuronal integrity, such as excitotoxicity and 
neurodegeneration (for a review, see Sebastião and Ribeiro, 2009a; 
Fowler et al., 2010). The present work has demonstrated that the 
modulatory action of A1 receptors over CB1 receptor-dependent 
signalling is not reciprocal (see Figure 4.1.9). Therefore, I 
hypothesize that cannabinoid signalling in the CNS acts more or less 
significantly as a function of the extracellular amount of endogenous 
adenosine.  
 In the future, it would first be helpful to further characterize the 
mechanisms of the A1-CB1 interaction by testing whether these 
receptors form a heteromeric complex. Heteromeric receptor 
complexes have unique ligand binding characteristics and could thus 
open the possibility of selective pharmacological targeting to specific 
neuronal populations (Ferré et al., 2009). 
 Accordingly, in the future, it is important to characterize the 
specific neuronal populations which co-express A1 and CB1 
receptors, as this interplay could prove to be relevant in other 
neurotransmitter systems, such as the serotonergic, the cholinergic 
and the dopaminergic system.  
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 The present thesis has shown a behavioural interaction between 
chronic caffeine administration and acute THC. Additionally, it not 
only provided further evidence that the chronic exposure to caffeine, 
even at moderate doses, can modify the levels of adenosine A1 
receptors, but also that non-adenosinergic receptors can be affected, 
as observed with CB1 receptors. The observations from the in vivo 
experiments have also raised various intriguing hypotheses (see 
chapter 5), since chronic caffeine appears to induce intricate 
modifications in the hippocampal circuitry that were made evident by 
the activation of CB1 receptors.  
 Chronic caffeine has previously been linked to increased 
behavioural effects of some drugs of abuse, such as nicotine, 
amphetamine and cocaine (Gasior et al., 2000; Justinova et al., 
2009). In the future, it is particularly important to better understand 
the full spectrum of the long-term neurochemical changes induced by 
chronic caffeine exposure, as it could be decisive for understanding 
the psychopharmacological profile of many drugs acting in the CNS. 	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